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Abstract
Insulin resistance is a characteristic of Type 2 Diabetes (T2D) and metabolic
syndrome, and until recently has not been considered in the context of Type 1 Diabetes
(T1D). A new classification, Double Diabetes, encompasses the presence of insulin
resistance in T1D. Unfortunately, these individuals are at significantly higher risk of
cardiovascular complications than those with T1D alone. In T2D, abnormal skeletal
muscle lipid metabolism and the accumulation of insulin desensitizing lipid metabolites
contribute the development of insulin resistance. There is some evidence to suggest this
occurs in the context of T1D as well. Exercise training is an effective means to enhance
insulin sensitivity, however, the fear of hypoglycemia remains a significant barrier in T1D.
Using our rodent model of T1D, the objectives of this dissertation were as follows: 1) To
determine whether insulin resistance is associated with increased skeletal muscle lipid
content, and whether this is ameliorated with aerobic exercise 2) to compare the efficacy
of combined aerobic and resistance exercise compared to aerobic exercise itself on skeletal
muscle oxidative capacity and lipid metabolism, and 3) to compare the effects of the
optimal exercise modality (combined exercise training) and the current recommendation of
intensive insulin therapy on insulin resistance and the composition of skeletal muscle lipid.
The findings of this dissertation were as follows: 1) There is an association between insulin
resistance and the accumulation of intramyocellular lipid metabolites, which is ameliorated
with aerobic exercise training. 2) Muscle lipid accumulation in sedentary T1D animals may
result from a reduced oxidative capacity, coupled to greater lipid uptake. Aerobic exercise
is sufficient to restore oxidative capacity, however combined exercise induces more robust
improvements to oxidative capacity. 3) Combined exercise significantly enhances insulin
sensitivity, while intensive insulin therapy is sufficient to prevent the drastic decline in
insulin sensitivity observed with conventional insulin treatment. Further, muscle lipid
composition differs between sedentary and exercised diabetic animals. These findings
indicate a reduction in oxidative capacity, coupled to increased lipid accumulation and
insulin resistance in sedentary T1D animals. Combined exercise is an effective modality
to enhance insulin sensitivity and modify muscle lipid metabolism.
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CHAPTER 1
1

« Introduction »

1.1 Type 1 Diabetes Mellitus
One of the earliest observations of Diabetes is recorded on the Ebers Papyrus dated back
to1552 BCE. While the disease had yet to be named, an Egyptian physician had recorded
treatments for “the passing of too much urine”1. By 1922, following the conception of insulin
by Frederick Banting, pharmaceutical company Eli Lilly & Co. struck a deal for the mass
production of insulin, allowing patients to manage the disease and serving as the primary
treatment strategy for Type 1 Diabetes to this day. In 1993, the ten-year Diabetes Control and
its Complications Trial was published, which confirmed the effectiveness of insulin for
managing blood glucose and reducing the complications associated with Type 1 Diabetes 1.
This year, a study reported successful interspecies transplantation of a pancreas, suggesting
transplantable human organs grown in animals may one day become a reality for the treatment
of Diabetes 2. Such novel findings continue to advance our understanding of the disease and
drive the scientific community to search for a Diabetes cure. Despite over a century of these
advancements, approximately 3.4 million Canadians with Diabetes require lifelong medication
for other diabetes-related illnesses, consistent insulin treatment and glucose monitoring, and
despite this, still experience an increased risk of cardiovascular disease 3,4.
There are two types of Diabetes, Type 1 Diabetes Mellitus (T1D) and Type 2 Diabetes
Mellitus (T2D). Normally, circulating blood glucose is maintained at approximately 3-5 mM
by pancreatic insulin secretion, which promotes glucose uptake into tissues for storage or
metabolism 5. T2D occurs when the pancreas is unable to produce sufficient insulin, or when

2

tissues become resistant to the insulin molecule, resulting in chronically elevated blood glucose
termed hyperglycemia. T2D often results from lifestyle and genetic factors, and for many
individuals is manageable through lifestyle modifications such as diet and physical activity as
well as medication 6. T1D, however, results from autoimmune mediated pancreatic beta cell
(β-cell) destruction and the subsequent inability to produce insulin 7. T1D patients often
present with weight loss, increased thirst and urination, fatigue, recurring infections, blurred
vision, and slow healing wounds 8. Following diagnosis, patients require exogenous insulin to
promote glucose uptake into tissues and prevent chronic hyperglycemia.
Multiple genes that predispose individuals to T1D have been identified. Several of these
genes are involved in immune function, such as Class II Human Lymphocyte Antigen (HLA)
genes 7. These genes code for proteins present on immune cells critical to the immune response,
and are the greatest T1D risk predictors. Similarly, lymphoid protein tyrosine phosphatase
(PTPN22), cytotoxic T lymphocyte associated protein (CTLA4) and interferon-induced
helicase C domain-containing protein 1 (IFIH1) are genes coding for immune factors
implicated in the onset of T1D 7. Short variable number tandem (VNTR) repeats within the
insulin gene itself are associated with a higher risk of T1D onset 7.
There are two predominant theories to explain the pathogenesis of T1D. In the “fertile
field hypothesis”, it is suggested that an initial infection may stimulate the development of
autoreactive CD8 immune cells, which destroy infected cells 9. Upon a subsequent infection,
or other environmental trigger, the autoimmune response is robust and may initiate β-cell
destruction, due to potential structural similarities between viral and pancreatic antigens 7.
The “accelerator hypothesis” suggests that T1D and T2D are the same disease set against
different genetic backgrounds

10

. It has been generally accepted that T1D results from an

3

autoimmune attack on pancreatic β-cells, and that T2D is a metabolic disorder. According to
the accelerator hypothesis, the only difference between T1D and T2D is the age of onset,
determined by the tempo of β-cell loss, not the cause. According to this hypothesis, the onset
of diabetes is determined by insulin resistance (the “driver”) and genotype (the “modulator”).
For individuals with T1D, a high genetic susceptibility requires little environmental pressure,
such as insulin resistance, to result in β-cell failure 11.
It likely that the onset of T1D results from a combination of genetic and environmental
factors, resulting in the autoimmune-mediated destruction of insulin-producing pancreatic βcells. In the absence of endogenous insulin, hyperglycemia results, necessitating insulin
therapy.
1.1.2 Insulin for the Management of Type 1 Diabetes Mellitus
The discovery of insulin by Banting and Best was critical to the management of T1D

12

.

For T1D patients, insulin is now self-administered via subcutaneous injection or via surgically
implanted insulin pump devices. Without sufficient insulin (termed hypoinsulinemia),
hyperglycemia results, and is an underlying factor in the development of several complications
including retinopathy, nephropathy, neuropathy and increased risk of cardiovascular disease
13

. The Diabetes Control and Complications Trial tested the “glucose hypothesis”, which

suggests hyperglycemia is the primary cause of complications in T1D. This trial compared the
effects of conventional and intensive insulin treatment on cardiovascular complications.
Briefly, patients with T1D were randomized into two different insulin treatment groups. The
conventional insulin therapy group was instructed to maintain HbA1c (glycated hemoglobin,
a measure of average blood glucose for approximately three months) at or below 13%, with
the use of insulin injections. The intensive insulin therapy group maintained significantly more

4

rigid glycemic control, striving to maintain HbA1c at approximately 6.5% with the use of
multiple daily insulin injections 14. Findings from the trial were the basis for recommending
an intensive insulin regime to patients with T1D, as intensive insulin treatment resulted in
significant improvements in retinopathy, microalbuminuria, neuropathy and microvascular
events

14

. The findings were so convincing that the trial was stopped, and all conventional

insulin treatment patients were switched to an intensive treatment. Following the reorganization of subjects, patients were followed from 1994 to 2017 (anticipated completion
date for primary outcome measure) as part of the Epidemiology of Diabetes Interventions and
Complications (EDIC) trial. This trial examined measures of atherosclerosis, including carotid
intima media thickness and coronary artery calcification. Despite converting all DCCT
patients to intensive insulin therapy, differences in these outcomes between the intensive only
patients and the newly converted patients widened over the first four years of the EDIC trail,
suggesting an effect of prior metabolic control on complications, termed metabolic memory 14.
More recent work has closely examined the DCCT and EDIC trials, and has identified
several limitations. Most notably, the exclusion criteria for the DCCT, which prevented
individuals with cardiovascular disease, hypertension, dyslipidemia, neuropathy and those
taking lipid-lowering drugs from participating in the trial

15

. It has been suggested that the

patients in the DCCT were otherwise healthy, and not representative of a T1D population 15.
Still, within this group of patients, evidence suggests factors other than glycemic control are
associated with adverse cardiovascular outcomes. For example, metabolic syndrome and
insulin resistance have been identified as better predictors of cardiovascular risk compared to
HbA1c

15

.

Analysis of a subgroup of DCCT patients revealed a synergistic role of

hyperglycemia and abnormal lipid partitioning, whereby individuals with increased low
density lipoproteins (LDLs), which are modified by advance glycation end products (AGEs)

5

are at a significantly increased risk of high carotid intima-media thickness 15. Further, DCCT
patients who were prescribed intensive treatment presented with an increased occurrence of
metabolic syndrome, and greater insulin resistance at baseline was associated with increased
risk of micro- and macrovascular complications 16.
While evidence highlighted in the DCCT and EDIC trials would appear to have confirmed
the “glucose hypothesis”, emerging studies have begun to question these outcomes and identify
limitations. It remains to be determined whether stringent glycemic control is the optimal
approach to reduce cardiovascular disease risk in T1D, despite DCCT findings providing the
rationale for the current prescription of intensive insulin therapy for T1D patients.
1.1.3 Type 1 Diabetes: Pathophysiology
T1D manifests when a genetic predisposition is triggered by a precipitating event, such
as viral or bacterial infection, or dietary allergens. In rare circumstances, monogenic forms of
T1D present, whereby mutation of a single gene when accompanied by other immune
conditions, disrupts regulatory pathways. Examples include IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, X-linked), which causes dysfunction of regulatory T cells
and approximately 80% of children with this mutation will develop T1D 7. Further, APS-1
(autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy) results in mutations in
the transcription factor AIRE, an autoimmune regulator and 20% of these individuals go on to
develop T1D 7.
Human Leukocyte Antigen (HLA) genes are a locus of genes that encode proteins on
the surface of cells for immune regulation. This locus is present on the HLA region of the
chromosome 6p21 (IDDM1), and is divided into class I and class II genes 7. Class II genes
have a promoter and pre-initiation complex, and are the strongest genetic determinants of risk

6

for the development of T1D. Individuals with DRB1*1501-DQA1*0102-DQB1*0602
haplotype are protected against T1D, while those with the DR3/4-DQ8 heterozygous haplotype
are susceptible to developing T1D

17

. Class I genes have a less prominent association with

T1D, however the HLA-B*39, HLA-A*02, and HLA-A*0201 are associated with T1D 18–20.
The insulin gene, at the IDDM2 locus on chromosome 11 is considered a primary
autoantigen in T1D 21. The degree of susceptibility depends on the number of variable tandem
repeat polymorphisms in the promoter region, with VNTR type I individuals having shorter
repeats significantly increasing the risk of T1D 22. VNTR type 1 reduces insulin transcription
in the thymus, reducing tolerance and promoting the onset of T1D

7,23

. PTPN22, encoding

lymphoid protein tyrosine phosphatase (LYP), IL2RA (interleukin (IL)-2 receptor- α) and
CTLA-4 (cytotoxic T lymphocyte-associated protein 4) are also genes implicated in the onset
of T1D 7,24.
Lastly, a gene for a sensor of viral infection, IFIH1 (interferon-induced helicase 1) may
contribute to the development of T1D 25. Increased function of IFIH1 may increase recognition
of specific viruses, exacerbating antiviral immunity and the production of type 1 interferons 7.
Viruses are an important precipitating factor in the pathogenesis of T1D, and are a component
of the “Fertile Field” hypothesis 9. In individuals with this genetic phenotype, a precipitating
event can trigger the onset of T1D. Viruses including coxsackie virus, enteroviruses, rotavirus,
and congenital rubella are all associated with the development of T1D 7,26–28. The Fertile Field
hypothesis suggests that a viral or bacterial infection causes pancreatic β-cells to upregulate
interferon (IFNα) and MHC Class I genes, which expose cells to attack by autoreactive T cells
with specificity for antigens in the pancreas. In this sense, an infection leads to a transient
period, in which the pancreas is a “fertile field” for autoimmune cell development

7,29

. A

subsequent series of immune events leads to the generation of autoreactive immune cells,

7

resulting in pancreatic -cell destruction and the cessation of insulin production. T1D results,
and patients require exogenous insulin to maintain normoglycemia 7.
1.2 Skeletal Muscle Metabolism
1.2.1. Insulin Signalling and Glucose Metabolism
In healthy pancreatic β-cells, insulin is synthesized when mRNA is translated into
preproinsulin. Preproinsulin is inserted into the endoplasmic reticulum, where its signal
peptide is cleaved, generating proinsulin. The peptide is cleaved again via endopeptidases
resulting in free C-peptide and insulin that accumulates in the cytoplasm of the β-cell, which
are subsequently released into circulation. This molecular process occurs in response to
increased blood glucose, which enters the beta cell via glucose transporters (GLUT). Glucose
enters glycolysis followed by subsequent metabolism in the mitochondria, and an increased
adenosine triphosphate: adenosine diphosphate ratio (ATP:ADP). The increased ratio triggers
membrane depolarization, calcium enters the β-cell and interacts with GTP (guanosine
triphosphate) and AC8 (adenylyl cyclase 8), activating cAMP (cyclic AMP) which activates
PKA (protein kinase A) and EPAC2 (a guanine nucleotide exchange factor) leading to insulin
exocytosis

30

. Insulin binding to its receptor initiates a variety of signalling pathways in

skeletal muscle, including GLUT4 translocation for glucose uptake.

Skeletal muscle

contraction also initiates signalling to enhance glucose uptake (see below).
Skeletal muscle metabolism is a complex and coordinated system, driven by demand
for energy in the form of ATP. To resynthesize ATP, an intricate cycle of enzymes facilitates
the breakdown of substrates including glucose and lipid. Regulation of substrate use depends
on a variety of factors, including sarcoplasmic reticulum calcium (SRCa2+), ATP breakdown
products, substrate availability and circulating hormones

31

.

When muscle energy

8

requirements are low, substrate entering the muscle cell is converted to glycogen (glucose
storage), diacylglycerol (DAG) and triacylglycerol (TAG) lipids (fatty acid storage).
Glucose entry into skeletal muscle during contraction is regulated by delivery, transport
and metabolism

32

. Delivery of glucose to the working muscle depends on blood flow and

capillary recruitment within the muscle, while transport and metabolism depend on the quantity
of transporter proteins and enzymes as well as their activity.

Skeletal muscle glucose uptake

relies primarily on the GLUT4 transporter, which translocates to the membrane in response to
contraction signalling as well as insulin signalling.
During contraction, increased intracellular calcium (Ca2+) and an increased AMP:ATP
ratio activates AMPK via Ca2+/calmodulin-dependent protein kinase (CaMKK), resulting in
phosphorylation of Akt substrate of 160 kDa (AS160) and TBC1D1, increasing 14-3-3 binding
to these proteins 33. This also inhibits Rab-GTPase-activating protein (GAP) activity toward
Rab isoforms, promoting conversion to more active GTP-loaded Rab, stimulating GLUT4
translocation and fusion with the plasma membrane and subsequent glucose uptake 33.
Insulin signalling is similar to skeletal muscle contraction signalling, as insulin binding
the insulin receptor (IR) promotes GLUT4 translocation and muscle glucose uptake. This
occurs, however, through the phosphatidylinositol (PI) 3-kinase pathway. The binding of
insulin to its receptor activates and phosphorylates it, resulting in the phosphorylation and
recruitment of insulin receptor substrate 1 (IRS-1)

34

. IRS proteins interact with the p85

regulatory subunit of PI3-kinase, activating and targeting the molecule to the plasma
membrane, where it generates phosphatidylinositol 3,4,5-triphosphate (PIP3) 34. PIP3 activates
the serine/threonine kinase PDK1, which phosphorylates AKT1 promoting GLUT4
translocation to the membrane 34. Other signals, such as nitric oxide (NO) and reactive oxygen

9

species (ROS) are increased with muscle contraction and promote GLUT4 translocation to the
membrane and increased glucose uptake 32.
Within skeletal muscle, glucose may be oxidized to produce ATP for working muscle,
or stored as glycogen. Upon entry into the muscle cell, glucose is phosphorylated and converted
to glucose-6-phosphate (G6P) by hexokinase 35. G6P may then proceed through the glycolytic
and oxidative pathways to produce ATP. When energy demand is low, insulin activates protein
phosphatase 1 (PP1), which dephosphorylates and activates glycogen synthase promoting
storage of glucose as glycogen 35. G6P is converted to glucose-1-phosphate (G1P), then uridine
diphosphate-glucose (UDP-glucose) by UDP-glucose-phosphorylase, and assembled into
glycogen by glycogen synthase 35.
1.2.2 Lipid Metabolism
In skeletal muscle, lipid metabolism consists of the oxidation of free fatty acids from
circulation, esterification and storage of free fatty acids, and breakdown of intramyocellular
lipid stores.
Acyl-CoA is formed by the addition of CoA to a free fatty acid, which enters the cell
by a variety of mechanisms. Circulating chylomicrons and very low density lipoproteins
(VLDLs) are too large to cross the skeletal muscle membrane, and require enzymatic
processing. Lipoprotein lipase hydrolyzes the TAG component in circulating chylomicrons
and very low density lipoproteins (VLDLs), releasing free fatty acids into the cytosol for
metabolism

36

. Circulating free fatty acids are smaller than chylomicrons and VLDLs, and

cross the muscle membrane via transporters, or through a “flip-flop” mechanism of diffusion
37

. CD36 (also called FAT, fatty acid translocase) is a fatty acid transport protein expressed in

skeletal muscle. CD36 translocates from an endosomal compartment to the muscle membrane

10

via AMPK signalling during muscle contraction as well as via PI3K mediated signalling
following insulin binding 38. Therefore, CD36 translocation and free fatty acid uptake mirrors
the mechanisms of GLUT4 translocation and glucose uptake. Fatty acid binding protein
(FABP), and fatty acid transporters (FATP1 and FATP4) are co-expressed with CD36 and
translocate to the skeletal muscle membrane in response to muscle contraction

39

. These

transport proteins facilitate fatty acid uptake under conditions of lower or normal circulating
lipid concentrations. However, during high circulating concentrations fatty acids at the outer
leaflet of the plasma membrane could enhance diffusion fluxes as these molecules “flip-flop”
from the outer to inner leaflet of the bilayer 37.
In the cytosol, free fatty acids form Acyl-CoA via Acyl CoA Synthase (ACS). This
Acyl-CoA may now undergo -oxidation, or may be stored as intramyocellular lipid,
specifically, TAG. -oxidation is the hydrolysis of fatty Acyl CoA to produce Acetyl CoA
(which enters the Krebs cycle) and the coenzymes NADH and FADH2, leading to ATP
generation. When free fatty acids are present in excess, or cellular energy demand is low, they
may be esterified for storage within skeletal muscle. Two key enzymes for intramyocellular
lipid esterification are glycerol-3-phosphate acyltransferase (GPAT) and diacylglycerol
acyltransferase (DGAT), which regulate the first committed step and final step, respectively
40

. GPAT catalyzes the acylation of sn-glycerol-3-phosphate (from glycolysis) at the sn-1

position, resulting in lysophosphatidic acid, while DGAT covalently links diacylglycerol and
a fatty acyl-CoA 41.
Finally, in addition to free fatty acid oxidation and esterification, skeletal muscle may
metabolize lipid stores for ATP generation. Intramyoceullular triacylglycerol (IMTG) is a
large source of substrate during exercise

42

. Hormone sensitive lipase (HSL) is an enzyme
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regulator of lipolysis, and is activated during exercise in response to calcium activation of
protein kinase C (PKC), which stimulates extracellular regulated kinase (ERK) 43. HSL is also
activated by epinephrine via protein kinase A (PKA)-mediated mechanisms

43

. During

lipolysis, adipose triglyceride lipase (ATGL) cleaves the first fatty acid off a triglyceride
molecule, producing diacylglycerol (DAG) and a free fatty acid

44

. DAG is subsequently

cleaved by HSL producing a free fatty acid and a monoacylglycerol, which is finally cleaved
by monoacylglycerol lipase (MGL) releasing glycerol and a fatty acid

44

. The cleaved fatty

acids may now enter the mitochondria for oxidation and generation of ATP for contraction.
1.2.3 Glucose and Lipid Overload
More recently, an interplay between glucose, lipids and thermogenesis within skeletal
muscle has been suggested

45

. Excess glucose and fatty acid oxidation results in significant

production of acetyl-CoA, which may overload the Krebs cycle, producing excess citrate.
Citrate is an allosteric activator of acetyl-CoA carboxylase (ACC), which catalyzes the
production of malonyl-CoA, a precursor in fatty acid synthesis. Further, via citrate lyase,
citrate will provide acetyl-CoA for ACC. This results in de novo lipogenesis within the muscle.
A futile cycle has been proposed, whereby PI3K activity increases glucose entry into the cell,
and, as described, drives de novo lipogeneis. AMP-activated protein kinase (AMPK) however,
phosphorylates ACC resulting in approximately 50-60% inhibition of activity and a subsequent
reduction in malonyl-CoA. AMPK also disinhibits carnitine palmitoyltransferase-1 (CPT-1)
an enzyme responsible for the transport of fatty acids into the mitochondria for oxidation.
Increased lipid oxidation produces acetyl-CoA, which overloads Krebs and drives de novo
lipogenesis, continuing the futile cycle.
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1.3 Insulin Resistance
As early as 1936, the concept of insulin resistance began to develop, as it was observed
that some patients required larger insulin doses than others to achieve similar effects on blood
glucose 46. Insulin resistance occurs when a “normal” or physiological concentration of insulin
produces a less than normal response, and may stem from alterations prior to insulin-insulin
receptor interaction, alterations in intracellular signalling, or alterations to the insulin receptor
itself 47.
The development of insulin resistance is determined by a variety of measures, including
measures of fasting glucose and insulin, insulin tolerance tests and oral glucose tolerance tests.
The hyperinsulinemic-euglycemic clamp, developed by DeFronzo et al. is considered the “gold
standard” for assessing insulin resistance

48

.

This test involves fasting patients overnight,

followed by an intravenous infusion of insulin at a constant rate to achieve hyperinsulinemia.
Insulin infusion will stimulate tissue uptake of glucose, and a subsequent reduction in blood
glucose. Blood glucose is measured at set intervals (usually every five to ten minutes) and
dextrose is infused simultaneously at a variable rate to reach normoglycemia. A greater
glucose infusion rate (GIR) suggests greater insulin action and sensitivity, while a lower GIR
is indicative of reduced insulin action.
Insulin resistance is a physiological state that contributes to the pathophysiology of
several cardiovascular and metabolic diseases

49

. It is a hallmark of T2D, and has been

observed among individuals with T1D, resulting in a state of Double Diabetes 15,16,50. Double
Diabetes occurs when patients with T2D also present with autoimmune markers against
pancreatic β-cells, or when T1D patients develop characteristics such as insulin resistance and
central adiposity

15,50

. Further, T1D individuals with a family history of T2D are at a
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significantly higher risk of developing Double Diabetes

15

. Among many T1D patients,

hyperglycemia as a result of T1D, and dyslipidemia, the result of central adiposity, may act
synergistically to substantially increase the risk of coronary heart disease (CHD) 15. Cleland
(2012) employs findings from the FinnDiane (Finnish Diabetic Nephropathy) study to illustrate
the emergence of different phenotypes associated with significantly increased mortality 15,51.
Those with poor glycemic control, coupled to insulin resistance and an atherogenic lipid profile
were at significantly greater risk of CHD 15,51 .
1.3.1 Insulin Resistance: Pathophysiology
The pathophysiology of insulin resistance is complex, as there are a variety of
mechanisms that impair insulin signalling, with the possibility of multiple factors acting
simultaneously. Excessive substrate oxidation, lipid intermediates, an altered cellular redox
environment, endoplasmic reticulum stress, and cytokines and macrophages have all been
implicated in the development of insulin resistance 52–54.
Chronically high circulating glucose contributes to skeletal muscle insulin resistance
via reactive oxygen species (ROS) formation. Excess oxidation produces electron leak from
the mitochondria and subsequent ROS formation

55

.

ROS are neutralized by cellular

antioxidant systems, such as glutathione coupled to NADH, which neutralizes H2O2 to 2H2O
54

. However, accumulation of ROS may overwhelm the antioxidant system and ROS that are

not neutralized negatively influence the insulin signal, particularly via JNK (c-Jun N-terminal
kinase) phosphorylation of IRS-1 55.
Ceramides are formed from the interaction between a saturated fatty acid (ie. palmitoyl
CoA) and L-serine to form dihydrosphingosine via serine palmitoyl transferase 1 (SPT-1) 56.
Dihydrosphingosine is then converted to dihydroceramide and finally, ceramide 56. Ceramides
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interfere with insulin signalling at the level of PKB/Akt, inhibiting GLUT4 translocation, as
PKB/Akt stimulates AS160

57

. In addition to interfering with the insulin signal, ceramide

activation of PKB/Akt reduces glycogen synthesis via inhibition of glycogen synthase kinase
3 (GSK3), and enhances lipogenesis and reduces lipolysis via stimulation of phosphodiesterase
3B (PDE3B) 56. This initiates cAMP and PKA signalling, and subsequent activation of fatty
acid synthase and inactivation of acetyl CoA carboxylase and acetyl CoA lyase.
DAGs are generated from free fatty acids that enter the muscle cell through transporters
such as CD36, FATPs, FABP, etc., through hydrolysis of lipoproteins via lipoprotein lipase,
or by passive diffusion across the membrane. Upon entry into the cell, fatty acids are converted
to fatty acyl-CoAs (FACoA), via acetyl CoA synthase 58. FACoAs may then enter β-oxidation,
then the mitochondria via carnitine shuttles for oxidation.

However, when lipolysis is

inhibited, or energy demands are low, excess FACoAs combine with glyceraldehyde-3phyosphate (G3P), and through a series of enzymatic reactions involving glycerol-palmitate
acyltransferase (GPAT) and acylglycerolphosphate acyltransferase (AGPAT) to produce DAG
58

. DAGs contribute to insulin resistance by impairing insulin signalling via interaction with

PKCθ

59

. PKCθ phosphorylates the insulin receptor at Serine 307, which impairs insulin

binding to initiate autophosphorylation of the receptor and activation of IRS-1

49

. This

subsequently fails to activate PI3K, and the signalling cascade that follows to mediate GLUT4
translocation. Interestingly, despite its negative effect on the insulin signal, increased skeletal
muscle DAG content is observed in individuals with normal or enhanced insulin sensitivity,
such as endurance athletes

53

. It is important to note, however, that endurance training

upregulates PGC-1α and mitochondrial content within the muscle 60. Further, exercise training
may enhance “metabolic channeling” of lipids, which refers to the direct delivery of fatty acids
(following TAG and DAG hydrolysis) to the mitochondria from the lipid droplet (LD)

54

.
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Metabolic channeling also includes the enzymes of β-oxidation, as they are organized into
multienzyme complexes; a series of catalytic reactions and the transfer of intermediates
between enzymes which prevents the diffusion into the aqueous environment

54

. Lastly, the

composition of DAG may determine its effect on insulin signalling, as DAGs composed of
saturated fatty acids (ie.di-C18:0) are associated with insulin resistance

61

.

Therefore,

endurance trained muscle is better equipped to oxidize intramuscular DAG, and the saturation
of DAG may differ in this population, perhaps preserving insulin signalling in these
individuals.
Excess circulating free fatty acids may also contribute to the onset of insulin resistance
through the formation of acylcarnitines. Increased free fatty acids in skeletal muscle are
converted to acyl-CoA via ACS. Acyl-CoAs are converted to acylcarnitines via CPT-1, and
enter the inner mitochondrial membrane. Here, via CPT-2, the addition of a CoA and removal
of carnitine results in acylcarnitine conversion to acyl-CoA, which may then undergo
oxidation. Under conditions of excessive free fatty acid accumulation in skeletal muscle, the
Krebs cycle is outpaced by fatty acid oxidation and acyl carnitines accumulate and are
transported out of the mitochondria 54. Acylcarnitines interact with nuclear factor kappa-lightchain-enhancer of activated B cells (NFκB), an inflammatory factor that exerts negative effects
on insulin signalling via JNK 62.
When circulating free fatty acids enter skeletal muscle and are not diverted toward
storage, they are oxidized. This is an essential function of muscle metabolism and an enormous
source of ATP for working muscle. However, in excess, free fatty acid oxidation stresses the
cellular redox environment, which disrupts the redox optimized ROS balance (R-ORB), and
subsequently impairs skeletal muscle insulin signalling

54

.

The nicotinamide adenine

dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) reducing equivalents resulting
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from oxidation of fatty acids reach the mitochondrial electron transport chain where they
donate electrons, which stimulates the transport of hydrogen ions across the membrane. This
is essential for ATP production, as it generates a proton pump. As hydrogen passes via ATP
synthase, the energy converts ADP to ATP. Excess flux of substrate through oxidative
pathways leads to an accumulation of reducing equivalents at the entry point of the electron
transport chain. Increased electron leak and formation of reactive ROS (H2O2) results. It is
also important to note that excess skeletal muscle fatty acids may bind peroxisome proliferatoractivated receptor alpha (PPARα) and upregulate acetyl CoA carboxylase and fatty acid
synthase 63.
In addition to altering the redox environment, excess fatty acid flux into the skeletal
muscle cell places an increased demand on cellular machinery, leading to the accumulation of
misfolded proteins from the endoplasmic reticulum (ER). Unfolded protein accumulation
stimulates phosphorylation of the unfolded protein response sensor inositol-requiring ER-tonucleus signalling protein 1 (IRE1). IRE1 forms a complex with adaptor protein TNF receptorassociated factor 2 (TRAF2) and activates JNK, which inhibits IRS-1 and impairs insulin
signalling

64

. Further, saturated fatty acids are not as freely converted to triglycerides as

unsaturated fatty acids and may travel to the ER resulting in alterations to its morphology and
function (ER stress)65.
In addition to abnormal substrate metabolism, inflammatory cytokines and
macrophages have been shown to drive the development of skeletal muscle insulin resistance.
Tissue necrosis factor alpha (TNF-α), a proinflammatory cytokine, exerts negative effects on
insulin sensitivity 52. The saturated fatty acid palmitate stimulates PKCθ and activates NF-κB,
which increases TNF-α gene expression 66. TNF-α alters AKT, AS160 and glucose transport
in skeletal muscle, and may also interfere with insulin signalling via activation of
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sphingomyelinase and subsequent production of ceramides 66–68. Inflammatory cytokines are
also released by macrophages. In response to circulating fatty acids, a macrophage may
become M1 polarized, its inflammatory phenotype

52,66

. When these macrophages are M1

polarized within the skeletal muscle fibres, they secrete inflammatory cytokines and exert a
paracrine effect on muscle cells. Interestingly, these macrophages may be located near the
skeletal muscle fibre, or be present in adipose tissue infiltrating muscle fibres 66.
1.3.2 Type 2 Diabetes: Pathophysiology
In T2D, insulin resistance may be coupled to insufficient insulin production. T2D is
the product of a gene-environment interaction, with a variety of genes predisposing an
individual to obesity and insulin resistance, and eventually T2D 69.
Leptin is a hormone that is particularly important in the development of obesity. Leptin
functions as an antilipogenic hormone in target tissues, and is also able to cross the bloodbrain-barrier, exerting effects in the hypothalamus

63

. Leptin binding to its receptors in the

hypothalamus results in reduced food intake, which would slow or prevent the onset of obesity.
However, saturation of transport across the blood-brain-barrier occurs when circulating leptin
concentration is lower than what is observed in obesity, suggesting this system may be
exhausted and the protective effects may be lost

63

. In other target tissues, leptin binds its

receptor and stimulates PPARα, CPT-1, UCP-2, and genes of fatty acid oxidation, increasing
oxidation and uncoupling to compensate for increased caloric intake 70,71.
In circumstances of uncompensated caloric excess contributing to obesity, circulating
leptin is insufficient to increase oxidation and uncoupling, and excess fatty acids activate
lipogenic genes including SREPB-1C, ACC, and FAS, increasing TAG, DAG, and ceramide
production

71

. These lipid intermediates may exert negative effects on the insulin signal
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(particularly at IRS-1). This reduces insulin-stimulated glucose uptake and glycogen synthesis,
as is observed in T2D 72. Further, chronically elevated circulating glucose depresses GLUT4
transporter content in skeletal muscle, contributing to reduced muscle glucose uptake

73

.

Historically, these lipogenic genes and handling of excess fatty acid and glucose was
advantageous, however with our increasingly sedentary modern lifestyle, they now predispose
individuals to insulin resistance and T2D 74.
Genetic susceptibility to T2D also occurs at the level of the pancreatic -cells. In a
normal -cell, obesity and insulin resistance contribute to increased cell function and growth
71

. As a result, hyperinsulinemia maintains normal glucose tolerance. However, a variety of

genes render β-cells susceptible to dysfunction and apoptosis (HNF1α, TCF7L2, mitochondrial
genes, etc.) 69. Often, by the time of T2D diagnosis, there is a 50% decrease in the number
pancreatic β-cells, and the remaining cells function at or below 25% of functional capacity 69.
The progressive nature of T2D can be described as the following cycle: a continuous decline
in β-cell function results in decreased insulin secretion and a subsequent increase in blood
glucose, which contributes to β-cell toxicity 69. Impaired insulin release also contributes to the
onset of insulin resistance at the level of the hypothalamus, stimulating increased food intake
(as discussed above). Further, hypoinsulinemia removes inhibition of adipose tissue lipolysis,
increasing the release of fatty acids into circulation which impair insulin signalling in -cells
and skeletal muscle, resulting in insulin resistance and T2D 69.
1.3.3 “Double Diabetes”: Type 1 Diabetes and Insulin Resistance
Type 1 and Type 2 Diabetes have long been considered two distinct metabolic diseases,
with T1D being a genetic, autoimmune disease and T2D being an interaction between
predisposing genetic factors and the environment. In 2001, the concept of “Double Diabetes”
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was formulated 75. Double Diabetes refers to T1D autoantibody positive individuals who are
also insulin resistant

75

. These individuals differ from T1D patients as they have a lower

frequency of MHC genes, and an increase in genes associated with the risk of T2D

76

.

Unfortunately, Double Diabetes is associated with an increased risk of cardiovascular
complications even compared to non-insulin resistant T1D patients 15.
In 2009, Wilkin proposed a hypothesis for the development of Double Diabetes termed
“The Accelerator Hypothesis”. This proposed that T1D and T2D are the same disorder of
insulin resistance, set against different genetic backgrounds with a different rate of progression
10,11

. According to this hypothesis, T1D is thought to develop in individuals who are extremely

genetically susceptible, who are subject to our obesity-promoting environment. This manifests
as a high degree of insulin resistance, coupled to a strong immune response in pancreatic islets,
leading to the onset of T1D. The rate of -cell loss determines when the disease presents, with
a moderate loss manifesting as adult onset diabetes, whereas a rapid loss results in childhood
onset diabetes 11. Regardless of the time of onset, insulin resistance (the “driver”) increases cell stress via glucotoxicity and lipotoxicity, which increases the immune response in
genetically predisposed (the “modulator”) individual

11

. Wilkin provides support for this

theory from a variety of epidemiological studies. For instance, the increasing rate of T1D
diagnoses parallels an increasing rate of childhood obesity

77,78

. Further, children who are

insulin resistant prior to developing T1D and those with the highest insulin resistance at
baseline are more likely to develop T1D than those who are less insulin resistant 79–81.
Perhaps the most interesting tenet of this hypothesis is the interaction between
predisposing genes and the environment. This suggests that while our susceptibility to T1D
may be fixed in terms of genetics, we have the capacity to alter our environment. Increasing
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physical activity, for instance, is a powerful method to reduce insulin resistance, and therefore
may protect against Double Diabetes. The role of exercise training in T1D will be discussed in
the subsequent pages.
1.4 Exercise and T1D
It is well-established that regular physical activity reduces the risk of chronic disease
and improves lifespan and quality of life across a variety of populations, including T1D

82

.

Many of these outcomes are the result of improved metabolic and cardiovascular health, such
as improved insulin sensitivity and cardiac function, as our lab has previously reported

83,84

.

Others have observed improvements to dyslipidemia, BMI, waist circumference, and aerobic
fitness following exercise training in T1D patients 85–89. Further, studies examining the effects
of different exercise modalities in T1D suggest that resistance training alone or in combination
with aerobic exercise may improve HbA1c and cholesterol and is associated with a reduced
risk of hypoglycemia 90–92.
1.4.1 Exercise Recommendations for T1D patients
The Canadian Diabetes Association currently recommends that individuals with T1D
engage in at least 150 minutes of aerobic exercise, in addition to a minimum of two bouts of
resistance training each week

93

. However, a major limitation to individuals with T1D

participating in exercise is a fear of hypoglycemia 94. Post-exercise hypoglycemia occurs as
the result of a reliance on exogenous insulin coupled to tissue (particularly skeletal muscle)
glucose uptake. In a nondiabetic individual, endogenous insulin production is suppressed,
while in those with T1D, the reliance on exogenous insulin may result in higher circulating
insulin during and following exercise. Therefore, this may exacerbate tissue glucose uptake
in the post-exercise recovery period resulting in hypoglycemia.
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There are, however, a variety of recommendations for preventing post-exercise
hypoglycemia, including ingestion of glucose to enhance blood glucose, in addition to reducing
the insulin dose 95. While this strategy reduces the risk of post-exercise hypoglycemia, there
is the risk of overcompensating and compromising long-term blood glucose control (HbA1c)
and weight gain

96

. More recent studies are examining various exercise modalities and the

incorporation of brief high intensity exercise and resistance training to reduce the risk of
hypoglycemia without ingesting additional glucose.
Brief and intermittent high intensity exercise (such as sprinting for a few seconds) has
been shown to increase circulating epinephrine, norepinephrine, growth hormone and lactate
96–100

.

The catecholamines epinephrine and norepinephrine stimulate hepatic glucose

production, and may contribute to a slower decline in blood glucose during exercise via
increased rate of glucose appearance

96,100,101

. This concept was observed in a study of

individuals with T1D that compared the effects of a 30 minute bout of cycling either at 40%
VO2max continuously or cycling at 40% VO2max with a 4 second sprint every 2 minutes

101

.

Results showed a reduced blood glucose decline following exercise in the group incorporating
the short sprints, and is likely the result of catecholamine-induced increases in hepatic glucose
production 100,101. These findings suggest the inclusion of brief high intensity bouts of exercise
may be advantageous for T1D patients engaging in exercise.
Resistance training is also gaining recognition as an exercise modality that may be safer
than traditional continuous aerobic exercise for individuals with T1D. As has been observed
with intermittent high intensity exercise, resistance exercise stimulates increased circulating
epinephrine, norepinephrine, growth hormone and lactate

96,102–104

.

Yardley et al. have

conducted several studies examining the effects of aerobic and resistance exercise in T1D
patients and has observed that resistance exercise is associated with a smaller initial decline in
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blood glucose than aerobic exercise

105

.

In an earlier study, T1D patients engaged in 45

minutes of running at approximately 60% V02max followed by 45 minutes of resistance training
or the resistance training preceding the running

105

. Performing the resistance exercise first

produced an attenuated decline in blood glucose during exercise, and reduced the frequency of
hypoglycemic events

92

.

It is hypothesized that the increase in circulating epinephrine

occurring during resistance exercise stimulates increased glycogen use during exercise,
preserving blood glucose 92,106.
1.4.2 Skeletal Muscle: Adaptations to Aerobic Exercise
Increased mitochondrial biogenesis is a hallmark adaptation to aerobic endurance
exercise training. The Krebs cycle and -oxidation occur exclusively within the mitochondria,
making this organelle essential to the cell’s energy supply. In 1967, Holloszy conducted one
of the earliest studies to demonstrate increased skeletal muscle mitochondrial protein content
following training in rats. Today, the effects of endurance training on mitochondrial biogenesis
are well documented 31,107–109.
A variety of stimuli occurring during endurance exercise initiate the transcription of
mitochondrial genes.

Many of these stimuli activate peroxisome proliferator-activated

receptor-gamma coactivator (PGC-1α), a co-transcriptional regulator. PGC-1α activates
several transcription factors, including NRF-1 and NRF-2 which interact with Tfam to drive
transcription and replication of mtDNA
nitric

oxide

(NO),

sirtuin

1

110,111

. Factors activating PGC-1α include AMPK,

(SIRT1),

target

of

rapamycin

complex

1/2/3

(TORC1/TORC2/TORC3), and p38 mitogen-activated protein kinases (p38 MAPK) among
others 110.
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Aerobic exercise results in greater energy turnover within the cell, and greater
conversion of ATP to ADP and AMP. These factors activate AMPK following binding to the
γ subunit 112. It has also been shown that AMPK has a glycogen binding domain, and is more
active when glycogen is low, especially during exercise

112

. AMPK is a regulator of cellular

anabolism and catabolism, and, through activation of PGC-1α and SIRT1, induces
mitochondrial biogenesis and promotes an oxidative fiber type

112

.

AMPK directly

phosphorylates PGC-1α, while SIRT1 deacetylates PGC-1α 112. Similar to AMPK, SIRT1 may
function as a sensor, becoming active during changes in the redox balance between NAD+ and
NADH

113

. Greater mitochondrial content bestows a greater ability to oxidize substrate, and

provide energy for contracting muscle. PGC-1α also moderates substrate flux through its
interaction with peroxisome proliferator activated-receptors (PPARs). PPARs bind with
retinoid X receptors (RXRs) to DNA sequences and upregulate gene expression of a variety of
genes associated with skeletal muscle lipid oxidation and fatty acid uptake

31,111

. Therefore,

exercise training promotes a greater capacity to oxidize metabolic substrates.
In addition to developing a greater capacity to oxidize substrate, exercise promotes
increased skeletal muscle glucose uptake from the circulation. AS160 is an AMPK target, and
when phosphorylated, it aids in the translocation of GLUT4 to the membrane

32

. Skeletal

muscle contraction has been shown to increase GLUT4 translocation and subsequent glucose
uptake. Our lab and others have observed increases in skeletal muscle GLUT4 protein content
following aerobic exercise training

83,114,115

. AMPK in addition to the CaMKII kinase, both

activated during muscle contraction, regulate GLUT4 transcription via HDAC4/5-MEF2
(histone deacetylase 4/5-myocyte enhancer factor 2) and MEF2-GEF (GLUT4 enhancer
factor) interactions 32.
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GLUT4 is also essential to glucose storage (as glycogen) in skeletal muscle. Following
uptake into the cell, hexokinase phosphorylates glucose to produce glucose-6-phosphate
(G6P). G6P is then converted to UDP-glucose, which, via glycogen synthase, is converted to
glycogen for storage in skeletal muscle. Increased GLUT4 protein content has been correlated
to greater glycogen storage following exercise 32,116,117.
Metabolic changes in skeletal muscle following exercise training are not limited to
glucose metabolism, as substantial improvements to lipid metabolism are observed. During
exercise, activation of AMPK inhibits ACCβ (acetyl CoA carboxylase beta), which catalyzes
the synthesis of Malonyl-CoA. Malonyl-CoA inhibits CPT-1 and fatty acid transport into the
mitochondria for oxidation. Therefore, inhibition of Malonyl-CoA synthesis leads to increased
fatty acid transport and subsequent oxidation 118. This enhanced lipid oxidation is coupled to
greater lipid storage and synthesis of IMCL 119. While excess skeletal muscle lipid content may
be detrimental, sequestering fatty acids in neutral TAG molecules and lipid droplets is
protective to the cell. Synthesis of these neutral lipid pools sequesters fatty acids and prevents
them from becoming harmful intermediates, and serves as an energy reserve for oxidation
during exercise.
Perhaps one of the most clinically relevant physiological adaptations to exercise is
enhanced insulin sensitivity. Greater insulin sensitivity results in improved glucose uptake and
regulation of blood glucose, preventing the negative effects of hyperglycemia in a variety of
tissues. There are several potential mechanisms underlying this effect, including greater
GLUT4 protein content and/or translocation, or reduced interference with the insulin signal via
reduced ROS production, DAG and ceramide content 120–122. Enhanced insulin sensitivity has
been observed immediately post-exercise, and may be the result of decreased skeletal muscle
glycogen content, AMPK activation, AS160 phosphorylation and enhanced lipid oxidation 123–
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128

. In addition to acute improvements to insulin sensitivity, aerobic exercise training elicits

more long lasting effects129.
1.4.3 Skeletal Muscle: Adaptations to Resistance Exercise
The American College of Sports Medicine defines resistance training as exercising a
muscle or muscle group against external resistance. Some of the well-understood adaptations
to resistance training include skeletal muscle hypertrophy, fibre type conversion, increased
capillary to fibre ratio and increased fat free mass 130.
Resistance training stimulates increased circulating insulin-like growth factor 1 (IGF1)

131

. IGF-1 initiates a signalling cascade which promotes skeletal muscle hypertrophy.

Briefly, IGF-1 binds its receptor and activates tyrosine kinase, stimulating autophosphorylation
creating insulin receptor substrate (IRS) docking sites. Phosphorylated IRS recruits and
activates PI3K, which generates PIP3 from PIP2 and acts as docking site for phosphoinositidedependent kinase 1 (PDK1) and Akt. PDK1 phosphorylates Akt which stimulates protein
synthesis via activation of mTOR and TORC1/TORC2 which stimulate ribosomal protein s6
kinase beta-1 (p70S6k) and eukaryotic translation factor 4E-binding protein (4E-BP1)
respectively, initiating protein translation and hypertrophy 31,132. Akt also phosphorylates and
inactivates GSK3, which releases its inhibition on eukaryotic translation initiation factor 2B
(eIF2B) 132. Resistance training has also been shown to phosphorylate IKK, linking cellular
stress to the activation of mTORC1 133.
In addition to skeletal muscle hypertrophy, resistance training is emerging as an
exercise modality associated with improvements to age-related skeletal muscle function
decline, oxidative capacity and mitochondrial function and insulin sensitivity

83,134,135

.

Resistance training acutely increases insulin sensitivity, improves insulin sensitivity in

26

overweight individuals, and increases insulin-mediated suppression of endogenous glucose
production

136–138

. The effects of resistance training on insulin sensitivity appear to occur

preferentially in skeletal muscle over the liver, and may be mediated by increases in key
enzymes and proteins in glucose metabolism including hexokinase, GLUT4, Akt, insulin
receptor, PKB, and glycogen synthase 139,140.
1.4.4 Skeletal Muscle: Adaptations to Combined Exercise
There is little doubt that exercise training, whether aerobic or resistance confers
positive metabolic adaptations in skeletal muscle. However, engaging in a combination of
these modalities was initially thought to impair fitness progression and improvement in each
specific activity. More recent work suggests that a combination of aerobic and resistance
training may produce substantial improvements to skeletal muscle metabolic health than either
activity in isolation.
A 2015 study examined the effects of alternating days of running and resistance training
on running performance

141

. This combined approach to training resulted in increased rating

of muscular fatigue, muscle soreness and reduced maximum voluntary contraction. Further,
concurrent training has been reported to hinder the capacity to develop strength, but not limit
the magnitude of V02max improvements

142

. This interaction between modalities has been

termed the “interference effect”. More recent evidence suggests there is no interference
between modalities, and the opposite may, in fact, occur. Short term-cycling followed by
maximal knee extensions, has been shown to activate vascular endothelial growth factor
(VEGF), cAMP-response element-binding protein (CREB), mechanistic target of rapamycin
(mTOR) and inhibit JNK, NFB, and MAPK 143. Interestingly, these genes were upregulated
in the cycling and knee extension (resistance exercise) group compared to the resistance
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exercise only group, suggesting that combining modalities increases expression of genes for
myofibre growth and oxidative capacity 143.
The interference effect may be a significant consideration for athletes striving for
optimal performance.

However, for individuals engaging in less rigorous exercise

participation, combining modalities may induce significant benefits. For example, citrate
synthase (CS) activity is a marker for oxidative capacity and has shown robust improvements
in activity following combined exercise training as opposed to either aerobic or resistance
training in isolation 143–145. The benefits of combined training have also been observed in the
study of individuals with T2D, as mitochondrial content and ability to metabolize substrate has
also been shown to increase to a greater degree following combined exercise compared to
aerobic exercise among T2D patients146.

Further, combined training is associated with

reductions in HbA1c and cholesterol and increased high density lipoprotein (HDL) among T2D
patients 147.
These studies of combined exercise training suggest that the combination of aerobic
and resistance exercise may elicit significant improvements to skeletal muscle metabolic
health. Resistance exercise may therefore be a powerful adjunct to aerobic exercise in the
management of skeletal muscle metabolic health and disease.
1.4.5 Cardiovascular Benefits of Exercise
The myocardium undergoes hypertrophy in response to exercise or as a pathological
adaptation to disease. Previous work from our lab has shown that sedentary diabetic animals
develop pathological cardiac hypertrophy, while exercise-trained animals show functional
cardiac hypertrophy in response to exercise

148

. Hypertrophy occurring in the sedentary

animals is a characteristic of T1D termed diabetic cardiomyopathy (DCM)

149,150

. DCM
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consists of ventricular dysfunction, abnormal intracellular calcium homeostasis and
contributes to myogenic cardiac dysfunctions
decreased

mitochondrial

respiration,

149,150

. The development of DCM occurs via

decreased

pyruvate

dehydrogenase

activity,

dysfunctional contractile and regulatory proteins, impaired calcium homeostasis 149,151,152. On
a larger scale, this dysfunction results from oxidative stress, inflammation, and cardiac
autonomic neuropathy (CAN) 153–156.
Exercise training has been shown to improve and even prevent the development of
DCM 157. Exercise has been shown to reduce contractile dysfunction and cardiac mortality in
T2D patients with insulin resistance 149,158. One of the most robust physiological adaptations
following exercise training is increased cardiac output

149,159,160

. Mechanisms underlying this

adaptation include increased cardiac pumping function and increased autonomic response, as
diabetes is associated with depressed catecholamine responsiveness 149,161–163.
Oxidative stress contributes to DCM via DNA damage.
increased superoxide (O-2) formation via the electron transport chain

Hyperglycemia drives
153,164,165

. Superoxide

dismutase (SOD) then increases nitric oxide (NO), leading to peroxinitrite (ONOO-) formation.
ONOO- induces DNA damage, slows glycolysis, the electron transport chain and ATP
production

153,165

.

Exercise training alleviates oxidative stress through enhancement of

myocardial antioxidant systems as well as reducing cytochrome c leakage 166. In streptozotocin
(STZ)-induced DCM, exercise increases the expression of extracellular SOD and attenuates
oxidative stress 167.
Hyperglycemia is also associated with an increase in inflammatory cytokines, which
damage the vascular endothelium and increased the risk of cardiovascular events

153,155

.

29

Exercise reduces circulating inflammatory cytokines, and in diabetic rodents, has been shown
to reduce tissue necrosis factor alpha (TNF-α) 168.
Individuals with poorly managed T1D often develop cardiac autonomic neuropathy
(CAN), consisting of cardiac sympathetic dysinnervation

153,156

. CAN is associated with

cardiovascular morbidity and mortality in T1D patients and is implicated in the pathogenesis
of diabetic nephropathy

169–171

. In rodent studies, low intensity resistance training attenuates

CAN, and among individuals with T2D, six months of exercise training significantly improves
CAN 172,173.
There is some disagreement as to whether patients with T1D achieve the same
cardiovascular benefits from exercise as other populations. In a retrospective analysis of the
DCCT, exercise was shown to have no effect on improvements in microvascular outcomes for
T1D patients

174

. However, a large study of T1D patients in Germany and Austria found an

inverse association between self-reported levels of physical activity and HbA1c, diabetic
ketoacidosis, dyslipidemia and hypertension

175

. It is possible, however, that no effect was

observed for patients in the DCCT based on the inclusion criteria of the trial, as these T1D
patients had no other complications 15. Given that this retrospective analysis reports no harm
to patients with T1D engaging in exercise, it should remain a valuable tool for the management
of T1D and for the maintenance of metabolic and cardiovascular health.
1.5 Rationale
Approximately 20% of T1D patients go on to develop insulin resistance, resulting in
what has been termed “Double Diabetes” 7. Cardiovascular disease is the leading cause of
morbidity and mortality among individuals with T1D and individuals with Double Diabetes
are at an even greater risk than those with T1D alone

50

. In T2D and metabolic syndrome,
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abnormal skeletal muscle lipid metabolism and accumulation of intramyocelluar lipids and
lipid metabolites have been shown to impair insulin signalling and contribute the development
of insulin resistance, which contributes to the development of cardiovascular disease

3,176

. It

is unclear to what extent skeletal muscle lipid metabolism is altered in the context of T1D. In
T2D, exercise training has been shown to alleviate lipid accumulation and is associated with
reduced insulin resistance

176

. Despite the numerous benefits of exercise, intensive insulin

therapy is currently recommended for the management of T1D 177. However, intensive insulin
therapy is associated with an increased risk of hypoglycemic events, and may contribute to the
development of insulin resistance 15,16.
Given the role of exercise training in restoring skeletal muscle lipid metabolism and
insulin sensitivity in T2D, it is possible these effects will be observed in T1D. However,
aerobic exercise is associated with significant risk of hypoglycemia, and we have observed
significant post-exercise declines in blood glucose in T1D animals that is not improved
following ten weeks of aerobic exercise training

178

. Recent findings reveal the beneficial

effects of combined (aerobic and resistance) exercise for the reduction of post-exercise
hypoglycemia 91,92,96. Resistance exercise performed before aerobic exercise maintains plasma
glucose during the aerobic exercise bout, and reduces the risk of post-exercise hypoglycemia
91,92

. Further, it is possible that the incorporation of both modalities as combined training

would confer the greatest improvements to insulin sensitivity and skeletal muscle lipid
metabolism, while reducing the risk of post-exercise hypoglycemia. Emerging findings
suggest resistance and aerobic exercise may act synergistically to enhance the adaptations to
exercise, and that combined exercise training may be superior to aerobic exercise alone for the
improvement of metabolic health 143–145. Therefore, to restore or enhance insulin sensitivity in
the context of T1D, it is necessary to examine the underlying molecular mechanisms, and the
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effect of insulin therapy and different exercise modalities on these processes. It is hypothesized
that abnormal skeletal muscle lipid accumulation will contribute to the development of insulin
resistance, and that exercise training will enhance insulin sensitivity through the amelioration
of muscle lipid metabolism.
1.6 Thesis Objectives
1. To determine whether insulin resistance in T1D is associated with increased skeletal
muscle lipid metabolites, and whether this is ameliorated with aerobic exercise training.
2. To examine whether combined (aerobic + resistance) exercise training improves
skeletal muscle oxidative capacity and lipid metabolism to the same degree as aerobic
exercise training alone in T1D.
3. To compare the effects of combined exercise and the current recommendation of
intensive insulin therapy on insulin resistance and skeletal muscle lipid composition in
T1D.
1.7 Overview and Thesis Development
The negative effects of intramyocellular lipids and lipid metabolites on the insulin
signalling cascade are well-understood in the context obesity and T2D

176,179,180

. It is not as

well understood in the context of T1D, although some have demonstrated an association
between intramyocellular lipid content and insulin resistance among T1D patients 181. Given
the rise of “Double Diabetes”, it is important to examine the mechanisms underlying the
development of insulin resistance, and whether exercise is an effective means to enhance
insulin sensitivity. The focus of this dissertation was to examine the effects of different
exercise modalities and insulin therapy on skeletal muscle lipid accumulation and insulin
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resistance. To do so, we used a rat model of STZ-induced, insulin treated T1D, which is
considered representative of humans with T1D 148.
The first objective of this thesis was to determine whether increased muscle lipid
accumulation was associated with insulin resistance in our model of T1D and whether this was
ameliorated with aerobic exercise training (Chapter 2). Using high performance liquid
chromatography, coupled to time-of-flight mass spectrometry, we identified several lipid
metabolites that differentiated skeletal muscle of sedentary, insulin resistant diabetic animals
from healthy control animals and from aerobically trained diabetic animals. Exercise training
also effectively restored insulin sensitivity in the sedentary diabetic animals to that of sedentary
non-diabetic animals. These findings led us to examine whether combined exercise training
induces comparable benefits compared to aerobic exercise, as it is associated with a reduced
risk of hypoglycemia (Chapter 3)

92,105,143–145,147

. We observed impaired oxidative capacity,

coupled to greater lipid accumulation in sedentary T1D animals. Aerobic exercise was
sufficient to restore oxidative capacity in T1D animals to that of non-diabetic control animals,
however, combined exercise training elicited significant improvements to oxidative capacity
and lipid storage. We then considered the importance of insulin therapy for individuals with
T1D and sought to compare the gold standard intensive management to combined exercise in
a conventionally treated group (Chapter 4). The combined group is maintained in a higher
glycemic range to mimic how patients with T1D manage their blood glucose in order to
exercise safely 96. The aim of this study was to examine the effects of the current recommended
treatment (intensive insulin therapy) compared to combined exercise training on a direct
assessment of insulin sensitivity via hyperinsulinemic-euglycemic clamp, and evaluate the
composition of skeletal muscle lipid stores.
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CHAPTER 2
2

« Metabolomic Response of Skeletal Muscle to
Aerobic Exercise Training in Insulin Resistant Type
1 Diabetic Rats »

2.1 Introduction
Type 1 Diabetes (T1D) is characterized by pancreatic β-cell destruction and the
inability to produce insulin and maintain glycemic control. A relatively new manifestation
of diabetes, termed “Double Diabetes” has been identified, whereby insulin deficiency is
coupled with the development of insulin resistance. The combination of these risk factors
is associated with a greater risk of cardiovascular disease than T1D or Type 2 Diabetes
(T2D) alone 1 .
While the etiology of insulin resistance in “Double Diabetes” remains to be
determined, it is understood that it does not parallel other insulin resistant states (i.e. T2D
or obesity), as patients with T1D often do not display associated factors such as obesity2.
It has been postulated that insulin resistance development in T1D stems from autoimmunerelated mechanisms, while other suggest that chronic hyperglycemia and the accumulation
of advanced glycation end products (AGEs) are causative factors

3–5

. In this respect,

glucotoxicity has been shown to lead to the activation of c-Jun N-terminal kinaes (JNK)
and protein kinase C (PKC) leading to disturbances in the insulin signalling pathway

6,7

.

This role for hyperglycemia and cellular glucotoxicity has gained further support, as
patients with T1D with a history of poor glycemic control are more likely to develop insulin
resistance 6.
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Increased intramyocellular lipid (IMCL) has also been implicated in the development of
insulin resistance in T1D patients. This may also be a result of poor glycemic management,
as glycosylated haemoglobin (HbA1C) is correlated to IMCL in T1D 8. Others have also
shown a positive relationship between insulin resistance and IMCL accumulation

9,10

.

Similar to T2D lipotoxicity may play a role in the development of insulin resistance in T1D.
In Zucker diabetic fatty rats, insufficient insulin leads to “metabolic overload” where
mitochondrial function does not meet increased lipid flux 11. In this case, free fatty acids
may be converted to diacylglycerol (DAG) or metabolized into ceramides; both of which
have been shown to interfere with insulin signalling

12,13

. We have established a rodent

model of T1D using multiple low-dose streptozotocin (STZ)- treatment and insulin therapy
to replicate poorly managed glycemic control observed in clinical T1D

14

. In previous

work, we have observed impairments in GLUT4 protein expression and the development
of insulin resistance which were improved with high intensity aerobic exercise training 14–
16

. Concomitant with increases in insulin sensitivity we have shown that exercise training

leads to reductions in blood lipid levels, decreased body mass, and decreased adipose tissue
mass in comparison to sedentary T1D animals

15,17

. The purpose of this study was to

determine whether insulin resistance development in a poorly controlled rodent model of
T1D is associated with disturbances in lipid metabolism; and whether aerobic exercisemediated improvements in insulin sensitivity are accompanied by changes in lipid
metabolism. We hypothesized that several insulin-desensitizing lipid metabolites would
be elevated in the skeletal muscle of insulin resistant T1D animals, indicative of impaired
lipid metabolism, and that exercise training would restore insulin sensitivity and skeletal
muscle lipid metabolism.
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2.2 Methods
Ethics Approval and Animals. Eight-week old male Sprague Dawley rats (N=48)
were obtained from Charles River Laboratories, and housed two per cage at constant
temperature and humidity on a 12-h dark/light cycle. Rats had access to water and standard
chow ad libitum. The experimental protocol followed the Principles of Laboratory Animal
Care (US NH publication No. 83-85, revised 1985). Ethics approval was obtained through
the University of Western Ontario Research Ethics Board, in accordance with Canadian
Council on Animal Care guidelines.
Experimental Groups. Animals were randomly divided into three experimental
groups; non-diabetic sedentary control (C, n=16), diabetic sedentary control (CD, n=16)
and diabetic aerobic exercise (DAE, n=16). Upon completion of the training study, each
group was divided into two subgroups. The first group (C, CD, DAE; n=8) underwent a
hyperinsulinemic-euglycemic clamp prior to sacrifice while the second group (C, CD,
DAE; n=8) did not undergo the clamp procedure but were sacrificed for tissue removal.
The second group of animals did not undergo the clamp procedure in order to preserve the
resting metabolic status of the muscle tissue for biochemical analysis.
Diabetes Induction. Upon arrival rats were housed for one week in order to
familiarize with their surroundings. Following this period, T1D was induced with multiple
low-dose STZ injections. STZ (20 mg/kg; Sigma Aldrich, Oakville, ON, Canada) was
injected into the intraperitoneal cavity for five consecutive days 18. Diabetes was confirmed
by two consecutive non-fasting blood glucose readings of ≥ 18.0 mmol/L. Subsequently,
insulin pellets (LinShin, Toronto, ON, Canada) were implanted subcutaneously. Insulin
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pellet/dosages were monitored and adjusted throughout the 10-week experimental study to
ensure daily non-fasting blood glucose concentrations of 9-15 mmol/L.
Exercise Training. Following the confirmation of diabetes and implantation of the
insulin pellets, rats were familiarized on a motor-driven treadmill for one week prior to the
onset of the exercise training program. This consisted of 15 minutes of progressive running
up to 30 m/min for five days. Once familiarized, the exercise training program consisted
of one hour of treadmill running at 27 m/min on a 6% gradient, five days per week for 10
weeks. This intensity of exercise has been shown to elicit 70-80% of VO2max

19

. To

maintain continuous running, rats received small blasts of compressed air on their haunches
if they broke a photoelectric beam at the rear of the treadmill.
Hyperinsulinemic-Euglycemic Clamp. To assess insulin resistance, eight animals
from each group (a subgroup of C, CD, and DAE) underwent a hyperinsulinemiceuglycemic clamp three days following the final bout of exercise training. Prior to the
clamp procedure animals were fasted for twelve hours and anaesthetized using isoflurane
and an intraperitoneal injection of urethane (25 mg/kg)/α -chloralose (4 mg/kg) 20,21. Once
an analgesic plane was confirmed, isoflurane was removed and the urethane/α -chloralose
mixture maintained the anaesthesia. A catheter was surgically inserted into the right jugular
vein for insulin and glucose infusion, and a second catheter was inserted into the right
carotid artery for blood sampling and blood glucose measurement. Insulin (Eli Lilly,
Toronto, ON, CAN) was infused at a constant rate of 10 mU/kg/min; 0.4  IU/mL. Glucose
(EMD Millipore, Darmstadt, HE, Germany) was infused at 20 mg/kg/min, 0.2 g/mL and
adjusted accordingly every 5 minutes until minute 20 and every 10 minutes thereafter to
maintain the blood glucose concentration.
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Tissue Collection. As noted above, eight animals in each group were euthanized for
tissue collection three days following the final bout of exercise by isoflurane anaesthesia
followed by exsanguination and cardiac excision. Due to tissue constraints, red portions of
the gastrocnemius muscle were flash frozen for oil red O staining, soleus (primarily red)
muscles were flash frozen for western blotting and the red portion of the tibialis anterior
was flash frozen for thin layer chromatography.
Skeletal Muscle Metabolomics. 100 ± 3 mg of the red portion of the vastus muscle
tissue was homogenized in 250 µ L of ice cold HPLC grade acetonitrile containing isatin
(5 µ g/mL) and flurazepam (25 ng/mL) as internal standards for 2 minutes in an ice bath.
Samples were vortexed, and centrifuged at 14000 rpm at 4 °C for 5 minutes. 120 µ L of
supernatant was removed and diluted with 30 µL of ultrapure water, for a final sample
containing 80% acetonitrile. A control injection was generated by creating a pooled sample
consisting of an equal volume of all injected samples. Samples were transferred to vials
and 1 µ L was injected in triplicate from each vial. Injections were randomized to reduce
error and pooled control samples were run every six injections. Chromatographic
separation was performed on a Waters Acquity Ultra Performance Liquid Chromatograph
system with separation achieved using an Acquity UPLC HSS T3 column (1.8 µ m particle
size, 100 mm × 2.1 mm). Column temperature was maintained at 45 °C in a Waters
ACQUITY UPLC I-Class system (Waters, Milford, MA). The mobile flow was set to 0.45
ml/min and consisted of water (A) and acetonitrile (B), both containing 0.1% formic acid.
UPLC conditions were as follows: 0–2 mins, 1–60% B; 2–6 mins 60–85% B; 6–8 mins 85–
99% B; 8–10 mins 99–1% B. A Waters XevoTM G2S-QTofMS was used for mass
spectrometry, and metabolites were measured in positive and negative electrospray
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ionization mode. Capillary voltage and cone voltage were set at 2 kV and 40 V respectively,
and the source temperature was 150 °C. Desolvation gas flow was set to 1200 L/h at 600
°C and the cone gas flow was 50 L/h. The data were acquired in centroid mode using an
MSE method with an m/z range of 50–1200. Leucine-enkephalin (500 ng/mL) was used as
the lockmass set at a flow rate of 10 µ L/min, measured every 10 seconds and averaged
over 3 scans.
Histochemistry. Oil Red O staining for neutral lipids was performed on frozen
sections of the red portion of the vastus muscle. Stock solution was prepared by combining
2.5 g of Oil Red O (Sigma Aldrich, Canada) and 400 ml isopropyl alcohol (99%) and stirred
for 2h. Working solution was prepared by mixing 1.5 parts stock with 1 part ddH20, which
was cooled and filtered. Slides were mounted in aqueous mounting media (10% PBS and
90% glycerol) and photographed using a Zeiss Axioskop Optical Microscope and Northern
Eclipse software.
Thin Layer Chromatography. Total lipid extraction was performed on the red portion
of the tibialis anterior muscle.

200-300 mg of minced tissue was submerged in

chloroform:methanol (2:1, v:v) and placed in the dark for 1 h. The extract was then poured
over Whatman filter paper into a glass tube. The extraction vessels were then rinsed and
vortexed with 1 mL of chloroform: methanol solution, filtered and added to the original
extract. Samples were dried under a steady air stream in a 30-40 C water bath for
approximately 1 h. The extract was weighed and diluted in 50 L chloroform:methanol
(2:1).
Lipid extracts and diacylglycerol (DAG) (1-Palmitoyl-2-Oleoyl-sn-Glycerol) Avanti Polar
Lipids Inc. Alabama, USA) standard were run on glass plates with a silica gel matrix
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(Analtech TLC uniplates, Sigma Aldrich, Canada) with a mobile phase consisting of
toluene:methanol (7:30, v:v). Plates were visualized using Iodine ACS Reagent (Sigma
Aldrich, Canada) in a closed glass chamber. Images were obtained using a flatbed scanner
and analyzed using ImageJ.
Western Blotting. Soleus muscle from each group was homogenized in a 1:10 (w:v)
ratio of homogenizing buffer (100 mmol/L NaCl, 50 mmol/L Tris base, 0.1 mmol/L EDTA,
0.1 mmol/L EGTA and 1% Tritonx100, pH 7.5), and a Bradford assay was used to
determine total protein content. Polyacrylamide gels were composed of 10% acrylamide
separating gel and 4% acrylamide stacking gel. Membranes were blocked in 5% non-fat
dry milk and Tris buffered saline (TBS), then incubated overnight at 4C in anti-hormone
sensitive lipase (HSL) antibody (1:1000) (ab45422, Abcam, Cambridge MA, USA).
Following secondary antibody incubation (BioRad goat-anti-rabbit IgG (H+L)-HRP
conjugated 1662408, and goat-anti-mouse IgG (H+L)-HRP conjugated 1721101 as per
manufacturer instructions), membranes were washed and visualized using a luminol-based
chemiluminescent substrate (BioRad Western C Enhanced Chemiluminescent Kit, 1705070) on a BioRad Chemidoc XRS imager. Densities were determined using Quantity One
software.
Data Analysis. Multivariate analysis of LC-MS data was achieved with Waters
Markerlynx with EZinfo 2.0 (Umetrics, Umea, Sweden) software packages. Following
normalization to total marker intensity in Markerlynx, peak intensities were transferred to
EZinfo. Pareto scaling dampened the selection of features with the highest variance.
Principle component analysis (PCA) and orthogonal partial least squares discriminant
analysis (OPLS-DA) were performed between control and diabetic control groups, and
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diabetic control and diabetic exercise groups using EZinfo. Metabolites were identified
using METLIN (http://metlin.scripps.edu) and HMDB (http://www.hmdb.ca) databases.
Fragmentation patterns for each metabolite were compared to putative database compound
fragmentation using MassFragment ®. For Western Blots, hyperinsulinemic-euglycemic
clamp and thin layer chromatography, group differences were tested using a one-way
ANOVA and Tukey’s post hoc test with a p value at p<0.05.

2.3 Results
Animal Characteristics. Animal weights and blood glucose concentrations are
shown for pre- and post-exercise training (Table 2.1). These values were obtained prior to
the onset of training and again upon the completion of 10 weeks of training. CD and DAE
animals had significantly higher blood glucose pre- and post-training. Body mass was
significantly lower in DAE compared to C and CD pre- and post-training.
Hyperinsulinemic-Euglycemic Clamp. Glucose infusion rates were significantly
lower in CD compared to C (p<0.05) and in CD compared to DAE (p<0.05), indicative of
insulin resistance in the diabetic control animals (Fig. 2.1). The glucose infusion rate was
not different between C and DAE (p>0.05), indicative of an exercise-mediated
improvement in insulin sensitivity.
Metabolomics. Metabolites in C and CD groups were described by OPLS-DA
(R2(Y)=0.90) with high predictive ability (Q2(Y)=0.58). Those in CD and DAE groups
were also described by OPLS-DA (R2(Y)=0.92) with high predictive ability (Q2(Y)=0.51).
Analysis of the red portion of the gastrocnemius muscle revealed a significant increase in
octadecenoic acid, palmitic acid, linoleic acid, arachidonic acid and docosahexaenoic acid

53
in CD compared to C. C demonstrated greater levels of adenosine diphosphate ribose (ADP
Ribose), adenylosuccinic acid and pantothenic acid compared to CD. Octadecenoic acid,
linoleic acid, arachidonic acid, docosahexaenoic acid and palmitic acid also demonstrated
the largest factor of change in the CD compared to DAE groups. Significant increases in
flavine adenine dinucleotide (FAD), pantetheine 4’-phosphate, pantothenic acid and ADP
ribose were observed for DAE compared to CD. Certain metabolites were not identifiable
(designated “unknown” in figures) likely due to poor fragmentation. (Figs 2.2 and 2.3)
(Table 2.2).
Neutral Lipid Staining. ORO staining for neutral lipids revealed darker stained
fibres in skeletal muscle of the CD group. The C group showed minimal staining, only
visible in a small number of fibres. The DAE group also showed minimal staining of fibres
compared to the D group, but there appears to be more lipid accumulation compared to C
(Fig. 2.4).
Diacylclycerol Content. Thin layer chromatography analysis of the red portion of
the tibialis anterior muscle revealed significantly greater DAG content in CD compared to
C (p<0.05). DAE did not significantly differ from C (p>0.05), suggesting exercise
improved skeletal muscle DAG content (Fig. 2.5).
Hormone Sensitive Lipase Content. We quantified HSL protein to determine
whether free fatty acid accumulation was a result of greater DAG and triacylglycerol (TAG)
hydrolysis. No significant differences were observed for HSL protein content of the soleus
muscle between groups (p=0.556) (Fig.2.6).
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Table 2.1. Animal characteristics at the onset and completion of the study. (*) indicates a
main effect for diabetes (p<0.05), (#) indicates a main effect of exercise (p < 0.05). Data
are represented as mean ± SE.

Figure 2.1. Hyperinsulinemic-euglycemic clamp assessment of insulin resistance.
(*)Control diabetic (CD) significantly different from control. (ψ) Diabetes aerobic exercise
(DAE) significantly different from control diabetic (CD). Data are expressed as mean ±
SE for each group.
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C

Peak Area (AU)

CD
DAE

Metabolite
Figure 2.2. Metabolite peak area. Data represent average chromatogram peak area ± SE
for each identified metabolite.
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Figure 2.3. Untargeted metabolomics in the red portion of the gastrocnemius. S-plot
comparison of control (C) and diabetic control (CD) (top). S-plot comparison of (CD) and
diabetes exercise (DAE) (bottom). The S-plot is a visual method for identification of
biomarkers. Variables farthest from the origin in the plot are deemed significant markers.
Each biomarker is identified with the elemental composition from the accurate mass and
comparison to fragmentation patterns from metabolite databases.
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Table 2.2. Metabolomic analysis. Metabolites that largely differentiate control (C), control
diabetic (D) and exercise-trained diabetics (DAE) from the red portion of the gastrocnemius
are presented.
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C

DAE

CD

Figure 2.4. Oil Red O. Representative images of ORO staining in red vastus of sedentary
control (C), control diabetic (CD) and diabetes aerobic exercise (DAE) groups.

C CD DAE

C CD DAE

S

DAG (AU)

C CD DAE C CD DAE

C

CD

DAE

Group
Figure 2.5. Thin layer chromatography quantification of DAG content in the red tibialis
anterior muscle. (*) The CD group demonstrated significantly greater DAG content
compared to C (p < 0.05). A representative chromatogram is shown. The representative
chromatogram has been cropped to show molecule of interest. Data are expressed as mean
± SE for each group.
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Figure 2.6. Hormone Sensitive Lipase protein content. Total soleus HSL protein content
in sedentary control (C), control diabetic (CD), and diabetes aerobic exercise (DAE). There
were no significant differences between groups (p = 0.556). Data are expressed as mean ±
SE for each group.
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2.4 Discussion
In the current study, we annotated and identified multiple metabolites that
differentiate skeletal muscle from insulin resistant (CD) animals from that of control (C)
animals.

Secondly, following aerobic exercise training, DAE animals showed

improvements in insulin sensitivity as well as changes in metabolite levels such that they
closely approximated those of healthy controls. Metabolites differentiating the CD group
from C and DAE include arachidonic acid and palmitic acid. Given the involvement of
these intermediates in inflammatory cytokine production and decreased GLUT4
translocation, these data suggest that insulin resistance in T1D elicits a shift toward the
intramyocellular accumulation of insulin desensitizing, pro-inflammatory metabolites.
Arachidonic acid (AA) is a precursor to multiple inflammatory cytokines, many of
which have been directly linked to the development of insulin resistance

22

. It has been

reported that reductions in phospholipid membrane AA following omega-3 feeding in rats
reduces the systemic inflammatory response induced by TNF-α 23. TNF-α is responsible
for the transcriptional suppression of genes relating to skeletal muscle glucose uptake
including GLUT4 and peroxisome proliferator-activated receptor gamma coactivator 1
alpha (PGC-1α) and can directly influence insulin signalling 24. Palmitic acid, a saturated
fatty acid (SFA), also impairs insulin signalling and is correlated to the development of
insulin resistance 25. Palmitic acid, as well as other saturated fatty acids (SFAs), impair the
insulin signal at many points, including reducing IRS-1 (insulin receptor substrate 1) and
protein kinase B (PKB/Akt) phosphorylation

26

. Lastly, linoleic acid, a polyunsaturated

fatty acid (PUFA), also differentiated our CD from C and DAE groups. Linoleic acid has
been shown to contribute to insulin resistance by reducing GLUT4 protein expression in
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L6 muscle cells

27

. Previously, we demonstrated that reductions in insulin sensitivity in

T1D rats were coupled to changes in GLUT4 expression, which were normalized along
with insulin sensitivity following six weeks of aerobic exercise training

15

. In line with

these results, the current study demonstrates that, concomitant with improvements in
insulin sensitivity, excess accumulation of palmitic acid, arachidonic acid, and linoleic acid
were not evident in exercise-trained diabetic animals. This suggests that aerobic exercise
training can ameliorate the insulin desensitizing effects of SFAs and PUFAs, possibly
through a reduction in total skeletal muscle free fatty acid content 28.
Skeletal muscle from diabetic control animals displayed greater levels of
docosahexaenoic acid (DHA) accumulation.

DHA has been shown to decrease the

transport efficiency of the sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA) pump,
through increased calcium (Ca2+) leak. It is believed that DHA causes futile SERCA
pumping thereby increasing the energy requirements to transport Ca2+ into the SR, as SR
Ca2+ pumps account for 40-50% of resting metabolic rate in mouse skeletal muscle

29,30

.

Indeed, Ca2+-ATPase activity and Ca2+ uptake has been shown to be elevated in cardiac
and skeletal muscle in experimental T1D animals. The resultant increased intracellular
Ca2+ is believed to play a role in the paradoxical increase in cardiac resistance to ischemiareperfusion injury in T1D animals, while elevated intracellular Ca2+ may increase
fatigability of skeletal muscle 16,31,32. Here, we observe that the increase in skeletal muscle
DHA levels in diabetic animals is normalized following exercise training. While it cannot
be ascertained whether a reduction in DHA is indicative of improved Ca2+ handling
efficiency in exercise diabetic animals, a reduction in Ca2+-ATPase activity and preserved
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Ca2+ uptake has been reported following high-intensity exercise training in skeletal muscle
of T1D patients 33.
In addition to lowered DHA levels, exercised diabetic animals exhibited elevated
levels of ADP ribose in comparison to diabetic control animals. ADP ribose is a Ca2+
mobilizing metabolite that has been shown to modulate the release of Ca2+ from the SR in
skeletal muscle 34. It has been shown that ADP-ribose accelerates cytosolic Ca2+ clearance
via SERCA activity 35. Elevated ADP ribose accumulation in exercised diabetic animals
may be indicative of other alterations in Ca2+ mediated processes involving glucose uptake
and metabolism

36

. For instance, ADP ribose formation is the primary signalling factor

responsible for exercise mediated GLUT4 glucose uptake in high fat fed insulin-resistant
mice. The increase in ADP ribose observed in the present study is likely indicative of
exercise-mediated enhancement of GLUT4 translocation and improved glucose uptake as
opposed to insulin mediated GLUT4 translocation 37.
Cyclic ADP ribose is generated by ROS-mediated activation of poly ADP ribose
polymerase (PARP), which splits NAD+ into nicotinic acid and ADP ribose

38,39

.

Mitochondrial ROS-mediated activation of PARP contributes to ADP ribose polymers
accumulating on glyceraldehyde 3-phosphate dehydrogenase (GAPDH), impeding the flow
of glycolysis and activation of pro-apoptotic factors 39. While this would seem contrary to
the known benefits associated with exercise, it is plausible that excess lipid accumulation
in diabetic animals may increase the pressure head point of entry into the mitochondria,
elevating ROS production, and impairment of glucose metabolism via ADP ribose
accumulation on GAPDH. It is yet to be determined how modifications of GAPDH and
other nuclear proteins may impact skeletal muscle; however, it may reflect an increase in
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the normal inflammatory process used to remove partially damaged muscle cells resulting
from higher levels of exercise 40.
Adenylosuccinic acid and inosine monophosphate (IMP) differentiated the C and
CD groups, suggesting altered purine metabolism in T1D. Purine nucleotides act as key
regulators of cell metabolism, serving as essential carriers of chemical energy such as ATP.
Purine metabolite state modulates the AMP/ATP ratio and can impact mitochondrial
function as well as AMPK activity which affects key cellular functions such as skeletal
muscle oxidative capacity and glucose oxidation, hepatic glucose output and glucose
sensitivity

41

. Similarly, the elevation in pantothenic acid, a precursor to coenzyme A,

would suggest that T1D led to a decrease in this cofactor critical for fatty acid metabolism.
Pantothenic acid did not differentiate DAE from C, suggesting a restoration of aerobic
metabolism with aerobic exercise training. In this respect, Flavin adenine dinucleotide
(FAD), pantetheine 4’-phosphate, ADP ribose and pantothenic acid differentiate DAE from
CD; indicative of improvements in oxidative pathways in our model of T1D. Enhanced
free fatty acid oxidation could reduce lipid esterification as well as ceramide and DAG
formation, preventing the inhibitory effects of these lipid species on the insulin signalling
cascade, restoring insulin sensitivity.
While these findings identify key markers that dissociate control from diabetic
animals, the mechanism underlying these differences in lipid metabolites remains unclear.
It is plausible that a greater uptake of free fatty acids with insufficient oxidation may
account for the observed changes 42. Hyperglycemia may also drive IMCL accumulation
as CPT-1 and β-oxidation are inhibited in this state 43. Moreover, circulating insulin hinders
TAG and DAG hydrolysis and stimulates fatty acid esterification, potentially contributing

64
to these changes

44,45

. In fact, we have previously shown significant reductions in the

insulin requirement of aerobically trained animals compared to diabetic control animals 16.
Studies have shown impaired insulin-stimulated glucose transport and increased ceramide,
DAG and TAG in skeletal muscle incubated in palmitate 46. Interestingly, a single bout of
prior exercise protected the insulin signal and some redistribution of free fatty acids toward
TAGs was observed

46

. Here, we demonstrate an increase in DAG content in the red

oxidative skeletal muscle of the CD group, which was normalized with aerobic exercise
training. It has been shown that DAGs interfere with the insulin signal via PKCθ, and
accumulation is associated with insulin resistance 13,47. Similarly, exercise has been shown
to preserve the insulin signal and redistribute free fatty acids toward TAG storage as
opposed to ceramides, which act at the level of PKCζ

48

. Our results align with other

studies, showing that DAG, but not ceramide, is more readily altered following lipid
infusion 49,50.
Given the elevation in DAG, we examined the expression of hormone sensitive
lipase (HSL), an enzyme that displays a high DAG substrate specificity and is considered
the major DAG hydrolase in several tissues

51

. Reduced HSL protein content could

potentially account for the increased DAG content observed in muscle, and this metabolite
has been shown to be decreased in skeletal muscle of obese, T2D individuals

52

. Our

findings reveal no significant differences in HSL protein content in soleus muscle between
groups. This finding is in accordance with others who have found no significant effects of
exercise training on skeletal muscle HSL content 53,54. It is important to note that diabetesrelated changes in HSL function may be due to posttranslational regulation, as endurance
training increases phosphorylation but not total protein content

55

. However, it has also
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been shown that reductions in HSL phosphorylation in obese subjects is entirely due to
lower HSL protein content, suggesting that muscle HSL content could be representative of
enzyme activity 56. Further work is required to ascertain the mechanisms involved in the
accumulation of DAG in skeletal muscle of T1D animals and the molecular means by
which exercise may reduce the accumulated levels of this lipid intermediate.
Possible limitations to this study should be addressed.

First, due to poor

fragmentation, we were unable to identify various ceramide species. In addition to DAG,
ceramide may also play an important role in insulin signalling impairment, as has been well
documented to occur in T2D

57

. Secondly, while Oil Red O staining provides a visual

representation of neutral lipid content within the muscle, it is unable to detect polar lipids
such as ceramides or phospholipids. This figure serves solely as a representative image,
and cannot be used to determine if the differences in total intramyocellular lipid content
between groups. Lastly, food intake was not measured in the current study. Considering
the impact of dietary behavior may shed further light on the causative factors leading to
changes in metabolite levels and metabolic rate in diabetic animals. While hyperphagia
has been well documented in STZ-T1D animals, it has been reported that hyperphagia is
restored and/or prevented in models of T1D following insulin treatment 58,59.
In summary, our results demonstrate that moderately hyperglycemic T1D rats
develop insulin resistance which is accompanied by significant alterations in skeletal
muscle lipid metabolism.

Ten weeks of aerobic exercise training improved insulin

sensitivity and ameliorate the accumulation of harmful insulin desensitizing lipid
intermediates in red oxidative skeletal muscle of T1D animals.

The underlying
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mechanisms by which exercise training improves skeletal muscle lipid metabolism and
insulin receptor function in T1D need to be determined.
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CHAPTER 3
3

« Aerobic and Resistance Exercise Effect Versus
Aerobic Only Training on Skeletal Muscle Lipid
Metabolism in a Rodent Model of Type 1 Diabetes »

3.1 Introduction
Type 1 Diabetes (T1D) results from the autoimmune-mediated destruction of
pancreatic beta cells, leading to insufficient insulin secretion and hyperglycemia.
Therefore, exogenous insulin therapy is required to maintain normal blood glucose levels.
A subset of patients with T1D are unable to maintain normal blood glucose levels despite
persistent glucose monitoring and insulin adjustment 1. Termed “double diabetes”, the
combination of immune-related T1D and insulin resistance has been shown to heighten
the risk for developing cardiovascular disease (CVD) 2.
Hyperglycemia and abnormal lipid metabolism are believed to initiate the
development of insulin resistance among individuals with T1D 3. Hyperglycemia increases
skeletal muscle lipid accumulation via inhibition of carnitine palmitoyltransferase-1 (CPT1), which in turn reduces mitochondrial beta-oxidation 4. Abnormal skeletal muscle lipid
metabolism has been shown to stimulate inflammation and the development of insulin
resistance, as excess lipid flux through oxidative pathways drives reactive oxygen species
(ROS) production and depletes reducing enzymes such as glutathione 5. Further, harmful
lipid species such as diacylglycerols (DAGs) and ceramides can exert inhibitory effects on
the insulin signalling pathways 6.
We have previously reported 10 weeks of aerobic exercise training can ameliorate
insulin resistance and improve cardiovascular function in a rodent model of T1D

7,8

.
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Further, regular aerobic exercise training leads to a reduction in skeletal muscle lipid
content including the accumulation of harmful insulin desensitizing lipid intermediates
such as DAG 7. It is well established that aerobic exercise induces significant skeletal
muscle adaptations including mitochondrial biogenesis, increased oxidative capacity
(citrate synthase activity) and glucose uptake

9–12

. Aerobic exercise also elicits a robust

increase in lipid oxidation and storage. AMPK activation during exercise alleviates CPT-1
inhibition permitting greater fatty acid transport into the mitochondria for oxidation 13.
Despite the known benefits to metabolic and cardiovascular health, aerobic training
remains difficult for patients with T1D, as there is a significant risk of post-exercise
hypoglycemia with this modality of exercise. We have previously observed a rapid and
significant reduction in blood glucose following acute aerobic exercise in T1D rats, which
persists following training

8,14

. The Canadian and American Diabetes Associations both

recommend a combined approach to exercise, involving both aerobic and resistance
training for individuals with T1D 15. Indeed, it has been shown that combining resistance
with aerobic exercise can attenuate the decline in blood glucose levels evident following
aerobic training alone

16

. Sustained elevations in catecholamines and/or growth hormone

as a result of resistance training is believed to enhance hepatic-mediated release of glucose
during the subsequent aerobic session 17,18. Resistance training elicits different adaptations
than aerobic training, including skeletal muscle hypertrophy, fibre type conversion and a
reduction in fat free mass 19. Further, resistance training increases mitochondrial function
and oxidative capacity as well as insulin sensitivity 20,21.
Little is known regarding the metabolic effects of combined modalities of exercise
in T1D patients. In non-diabetic individuals, an “interference effect” has been reported
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whereby simultaneously training for strength and endurance hinders strength development,
reduces maximum voluntary contraction and running capacity

22,23

. In obese individuals

and patients with T2D, evidence would suggest that despite impairments to athletic
performance, combined training may significantly improve oxidative capacity, glycemic
control, insulin sensitivity, and body composition 24–26. Moreover, evidence has shown that
the combination of aerobic and resistance exercise is associated with greater improvements
in mitochondrial capacity, demonstrated by elevations in citrate synthase activity to a
greater extent than either aerobic or resistance training alone 24,27,28.
The combination of aerobic and resistance training has been suggested as an
effective strategy to mitigate the risk of exercise-mediated hypoglycemia, and may provide
substantial benefits for cardiovascular and metabolic health

16,29,30

. Work is needed to

better understand the effects of combined (aerobic and resistance) exercise on skeletal
muscle metabolism among individuals with T1D, particularly as it pertains to the
metabolism of intramyocellular lipids within skeletal muscle. The purpose of this study
was to determine whether combined (aerobic and resistance) exercise is an effective means
to improve skeletal muscle oxidative capacity and lipid metabolism. We hypothesized that
combined exercise training would reduce intramyocellular lipid content and enhance
oxidative capacity in skeletal muscle of rodents with T1D to an equal or greater extent than
aerobic training alone.

3.2 Methods
Ethics Approval and Animals. Eight-week-old male Sprague-Dawley rats were
obtained from Charles River Laboratories (St. Constant, QC, Canada), and housed two per
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cage. Temperature and humidity were maintained constant with a 12-h dark/light cycle.
Animals received standard chow (Prolab-RMH-3000; PMI Nutrition International) and
water ad libitum. Ethics approval was obtained through the University of Western Ontario
Research Ethics Board, in accordance with the Canadian Council on Animal Care
guidelines.
Experimental Groups. Rats were randomly assigned to one of four groups: Control
sedentary (C, n=12), Diabetic insulin-treated sedentary (CD, n=12), Diabetic insulintreated high intensity aerobic exercise (DAE, n=12), and Diabetic insulin treated combined
aerobic and resistance exercise (DARE, n=12).
Diabetes Induction. Rats were housed for one week after arrival to familiarize with
their surroundings.

T1D was induced with multiple low-dose streptozotocin (STZ)

injections (week 1). STZ (20mg/kg; Sigma Aldrich, Oakville, ON, Canada) was injected
into the intraperitoneal cavity for five consecutive days. Diabetes was confirmed with two
non-fasting blood glucose readings of ≥18.0 mmol/L.

Subsequently, insulin pellets

(LinShin, Toronto, ON, Canada) were implanted subcutaneously, and dosages were
monitored and adjusted throughout the experimental study to maintain blood glucose
concentrations between 9-15 mmol/L. This range of blood glucose is representative of
levels patients with T1D utilize while participating in a regular exercise program in order
to avoid the risk of post-exercise hypoglycemia 31.
Exercise Training. Upon the completion of diabetes induction and insulin pellet
implantation, rats in the exercise training groups (DAE, DARE) underwent a
familiarization protocol (experimental week 3) and exercised for the following 12 weeks
(experimental weeks 4-15). Treadmill familiarization consisted of progressively increased
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running up to 27 m/min on a six percent grade over five days. Rats were encouraged with
small blasts of compressed air if they ceased running and broke a photoelectric beam at the
rear of the treadmill.

DARE rats were also familiarized to resistance training, and

performed 10 vertical ladder climbs per day with weights attached to the base of the tail
(5%, 15%, 20% and 35% of rat body mass). Training for the DAE group consisted of
treadmill running 5 days per week at 27 m/min on a six percent grade for one hour. The
DARE group alternated days of treadmill running (27 m/min on a six percent grade for one
hour) with climbing sessions consisting of climbing with 50%, 75%, 90%, and 100% of
maximum lifting capacity. Maximum capacity was determined after every fourth day of
resistance training with the sequential addition of 30 grams of weight until exhaustion. The
increase in maximal carrying capacity following the 12 weeks of combined exercise
training is reported in Table 3.1.
Body Mass and Blood Glucose. Body mass and non-fasting blood glucose was
measured weekly. Blood glucose was measured via blood collection from the saphenous
vein, using a Freestyle Lite Blood Glucose Monitoring System (Abbott Diabetes Care,
Mississauga, Ontario, Canada).
Tissue Collection. Animals were euthanized three days following the final bout of
exercise (training week 12) by isoflurane anaesthesia and exsanguination via cardiac
excision. Animals were euthanized three days following the final bout of exercise to avoid
any residual effects of acute exercise in tissue analysis. Following sacrifice, serum was
collected, centrifuged and flash frozen in liquid nitrogen.

Red portions of the

gastrocnemius (red gastrocnemius) muscle were collected and flash frozen, while the soleus
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muscles were mounted on cork and frozen in isopentane cooled with liquid nitrogen.
Tissues were stored at -70°C for later analysis.
Blood Lipids and Free Fatty Acids. Serum triglycerides, total cholesterol, high
density lipoprotein (HDL), low density lipoprotein (calc) (LDL), and cholesterol:HDL
analysis was performed at the University Hospital (London, ON, Canada). Serum free fatty
acids were quantified using a commercially available colorimetric ELISA kit (ab65341,
Abcam, Cambridge MA, USA).
Serum Insulin and HOMA-IR. Fasting serum insulin was quantified using a
commercially available ELISA kit (Alpco, Salem NH, USA).

Homeostatic model

assessment of insulin resistance (HOMA-IR) was calculated using the following equation:
µ
𝑚𝑚𝑜𝑙
) × 𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 ( 𝐿 ))
𝑚𝑙

(𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑠𝑒𝑟𝑢𝑚 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 (
=

22.5

Histochemistry. Oil Red O (ORO) staining for neutral lipids was performed on 10
µm sections of frozen soleus muscle, as reported previously 7. Briefly, following staining
in 0.5% ORO (Sigma Aldrich, Canada) in propylene glycol overnight, slides were washed
in distilled water, and allowed to dry and mounted in an aqueous mounting medium (10%
PBS, 90% glycerol). Images were obtained at 10x magnification on an Olympus BX50
microscope, exposure 10.08 ms, gain 30.72%, offset 30.98%.
Citrate Synthase Activity. Citrate synthase (CS) activity was measured in the red
gastrocnemius muscle. Muscle samples (100 mg) were homogenized 1:20 (w:v) in buffer
containing 100mM KPO4, 5mM EDTA, 5mM EGTA, pH 7.4. Samples were then rediluted 1:20 (v:v) and freeze fractured by freezing samples at -80C and thawing to room
temperature three times. On a 96-well plate, 2 µL sample, Tris buffer (100 mM Tris), acetyl
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CoA (3mM), 5,5’-Dithiobis (2-nitrobenzoic acid) (DTNB) and oxaloacetate (5mM) were
combined and rate of absorbance change was read at 412 nm. Samples were run in
triplicate.
Activity was calculated from the following equation:
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = ∆𝐴405 / min

∆𝐴405 / min× 𝑉 (𝑚𝑙) × 𝐷𝐹
𝜀 𝑚𝑀 × 𝐿 (𝑐𝑚) × 𝑉𝑒𝑛𝑧 (𝑚𝑙)

Where ∆A405/min is the rate, V(ml) is the total volume of the well, DF is the dilution factor,
εmM is the DTNB extinction coefficient, L (cm) is microplate path length, and Venz(ml) is
the sample volume.
Western Blotting.

A second portion of the red gastrocnemius muscle

(approximately 100 mg) from each group was homogenized in a 1:10 (w:v) ratio with
homogenizing buffer (100 mmol/L NaCl, 50 mmol/L Tris base, 0.1 mmol/L EDTA,
0.1mmol/L EGTA and 1% Tritonx100, pH 7.5). A Bradford assay was used for total
protein content. Samples were run on polyacrylamide gels and transferred to nitrocellulose
membranes. Membranes were blocked in non-fat dry milk or BSA and Tris buffered saline
with Tween20 (TTBS) and incubated overnight in primary antibody (CD36 1:2500,
ab133625; Lipin-1 2ug/mL, ab181389; IRS-1, 1:750, ab52167, Abcam, Cambridge MA,
USA; phospho-IRS-1 Ser1101, 1:750, #2385 Cell Signalling, Danvers MA, USA).
Following secondary antibody incubation (BioRad goat-anti rabbit IgG (H+L)-HRP
conjugated 1662408 and goat-anti-mouse IgG (H+L)-HRP conjugated 1721101 as per
manufacturer

instructions),

membranes

were

washed

and

visualized

using

chemiluminescent substrate (BioRad Western C Enhanced Chemiluminescent Kit, 1705070) on a BioRad Chemidoc XRS imager. Densities were determined using Quantity One
software).
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Data Analysis and Statistics. Body weight, blood glucose, blood lipids and free fatty
acids, CS activity and Western Blot densities were compared via one-way ANOVA with
Tukey’s post hoc test and a p value set at <0.05. Maximal carrying capacity was compared
with a paired t-test with a p value set at <0.05. For non-parametric data, a one-way ANOVA
on ranks was performed. Statistical analysis was completed with GraphPad Prism.

3.3 Results
Animal Mass, Blood Glucose and Lifting Capacity. Mass (g) and blood glucose
(mmol/L) values are presented for experimental week 14 (upon the completion of the 12
weeks of training) (Table 3.1). Following 12 weeks of training, mass is significantly
reduced in DAE and DARE compared to C, while blood glucose levels in all diabetic
groups is significantly higher than in non-diabetic sedentary controls (C) (p<0.05).
Maximal lifting capacity in the DARE group is significantly increased at week 12 of
training compared to week 1 (p<0.001) (Table 3.1).
Serum Lipids, Free Fatty Acids and HOMA-IR. Serum lipid concentrations
(mmol/L) are presented in Table 3.2. There were no significant differences between groups
for triglyceride, total cholesterol, HDL, LDL (calc), cholesterol:HDL, or serum free fatty
acids. HOMA-IR was significantly reduced in DARE compared to CD (p<0.05) (Table
3.2). These results indicate that DARE had significant improvements in insulin sensitivity
in comparison to CD animals.
Oil Red O Staining. Representative images of Oil Red O staining for neutral lipids
revealed darker staining in CD and DARE groups indicative of elevated neutral lipid
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accumulation. There appears to be minimal fibre staining in the DAE and C groups.
(Fig.3.1).
Citrate Synthase Activity. Citrate synthase (CS) activity was measured in the red
gastrocnemius muscle. Results of the activity assay revealed significantly lower CS
activity in the CD group compared to C and DARE (p<0.05). The DARE group showed
significantly elevated CS activity compared to CD and DAE groups, indicative of
improvements in oxidative capacity of red skeletal muscle (p<0.05). (Fig. 3.2).
Western Blot Analysis. CD36 protein content was significantly higher in the CD
group compared to C and DARE (p<0.05). CD36 functions in long chain fatty acid uptake,
suggesting increased uptake in the CD animals (Fig. 3.3). Lipin-1 facilitates the conversion
of phosphatidic acid to diacylglycerol within skeletal muscle. Lipin-1 protein content was
significantly elevated in DARE compared to C (p<0.05), indicative of increased
diacylgycerol and/or triacyglcyerol storage in this group. (Fig. 3.4).
Given the role of diacylglycerol in the inhibition of the insulin signal, we examined IRS-1
phosphorylation of Ser1101.

Quantification of the ratio of phosphorylated to non-

phosphorylated IRS-1 revealed no significant differences between any of the groups
(p>0.05). (Fig. 3.5).
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Week 14:

C (n=12)

CD (n=12)

DAE (n=8)

DARE (n=6)

Mass (g)

617.75 ± 18.61

552.00 ± 19.76

510.13 ± 15.30*

527.33 ± 20.45*

Glucose
(mmol/L)

4.2 ± 0.13

17.26 ± 0.66#

15.66 ± 0.46#

16.65 ± 1.68#

-

-

Week
1:
437.43 ± 25.35

Maximal Lifting Capacity (g)

Week
12:
1689.14 ±67.02°

Table 3.1. Animal characteristics upon completion of the study. Animal mass (g): (*)
Significantly different from control (p<0.05). Blood glucose (mmol/L): (#) Significantly
different from control (p<0.001). Maximal lifting capacity (g): (°) Week 12 is significantly
greater than week 1 in the DARE group (p<0.05). Values are presented as mean ± SE.
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C (n=12)

CD (n=12)

DAE (n=8)

DARE (n=6)

Cholesterol
(mmol/l)

1.65 ± 0.08

1.67 ± 0.09

1.62 ± 0.10

1.71 ± 0.08

TRG
(mmol/l)

1.47 ± 0.16

1.43 ± 0.23

1.34 ± 0.37

0.80 ± 0.08

HDL
(mmol/l)

1.10 ± 0.08

1.14 ± 0.06

1.2 ± 0.07

1.36 ± 0.07

LDL
(calc)
(mmol/l)

-0.11 ± 0.44

-0.19 ± 0.08

-0.20 ± 0.12

0.01 ± 0.08

Cholesterol:HDL
(mmol/l)

1.55 ± 0.08

1.52± 0.12

1.36 ± 0.65

1.27 ± 0.05

C (n=8)

CD (n=5)

DAE (n=5)

DARE (n=5)

Serum
FFA
(µM)
HOMA-IR

1184.92
761.14

± 2212.62
642.712
CD (n=11)
4.72

± 3061.82
836.37
DAE (n=7)
1.33

± 1312.70
249.25

±

DARE (n=7)
0.41*

Table 3.2. Blood lipid analysis of terminal serum (week 14) and HOMA-IR. There were
no significant differences between group. HOMA-IR: (*) significantly reduced in the
DARE group compared to the CD group (p<0.05). TRG, triglyceride; HDL, high density
lipoprotein; LDL, low density lipoprotein; FFA, free fatty acid; HOMA-IR, homeostatic
assessment of insulin resistance. Values are presented as mean ± SE, HOMA-IR data are
presented as median.
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Figure 3.1. Representative images for Oil Red O neutral lipid staining.

Figure 3.2. Citrate synthase enzyme activity in the red portion of the gastrocnemius. (*)
Rate in CD is significantly lower than in DARE and C (p<0.05). (#) Rate in DARE is
significantly greater than CD and DAE (p<0.05). Values are presented as mean ± SE.
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Figure 3.3. Fatty acid transporter CD36 protein content in the red portion of the
gastrocnemius. (*) Significantly greater in CD compared to C and DARE (p<0.05). Values
are presented as mean ± SE.

Figure 3.4. Lipin-1 protein content in the red portion of the gastrocnemius. (*)
Significantly greater in DARE compared to C (p<0.05). Values are presented as mean ±
SE.
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Figure 3.5. Total pIRS-1 Ser1101: IRS-1 protein content in the red portion of the
gastrocnemius. Protein content is not significantly different between groups (p=0.8735).
Values are presented as mean ± SE.
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3.4 Discussion
The purpose of this study was to examine the effects of combined exercise
training versus aerobic only exercise training on skeletal muscle oxidative capacity and
intramyocellular lipid content in T1D rodents. We hypothesized that combined training
would result in reduced skeletal muscle lipid accumulation and enhance oxidative
capacity to a similar or greater extent than aerobic exercise alone. Results from this study
indicate that combined exercise training offers a significant improvement to skeletal
muscle oxidative capacity as well as insulin sensitivity measures, beyond that evident
following aerobic exercise. Contrary to our original hypothesis, unlike aerobic only
exercise training, combined exercise did not reduce skeletal muscle lipid content.
However, a reduction in CD36 and increased levels of a triglyceride converting factor
Lipin-1 would suggest that the skeletal muscle of combined exercise trained rats
demonstrates increased lipid storage capacity. This, coupled to significantly enhanced
citrate synthase enzyme activity indicates combined exercise confers a greater capacity to
channel substrate toward neutral lipid stores or oxidation, preventing the accumulation of
insulin-desensitizing lipid metabolites.
The measurement of CS activity is valuable marker to evaluate skeletal muscle
oxidative capacity and mitochondrial density 32. In the current study, we observe a
significant reduction in CS activity in CD animals compared to C, indicative of reduced
muscle oxidative capacity in our rat model of T1D. This may be the result of lipid
accumulation and uncoupling of oxidative phosphorylation in the slow-twitch muscle 33.
Our findings are consistent with other animal models of diabetes, as STZ-induced
diabetic mice and Zucker diabetic fatty rats demonstrate reduced CS activity and
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oxidative capacity 33,34. Further, following acute exercise, patients with T1D demonstrate
a reduction in blood citrate levels and attenuated lipolysis, which may stem from the
effects of exogenous insulin treatment 35.
Aerobic only exercise training restored, or at least, prevented the decline in
oxidative capacity evident in the CD group. It is well-established that aerobic exercise
training substantially improves CS activity through a variety of mechanisms, including
factors such as AMPK-induced mitochondrial biogenesis

36

. Interestingly, we observed a

substantial increase in CS activity in the DARE group compared to DAE despite fewer total
bouts of treadmill running (aerobic exercise). This finding suggests that aerobic and
resistance exercise training may produce a synergistic effect on muscle oxidative capacity.
Indeed, others have observed that combined exercise training can increase oxidative
capacity to a greater extent than aerobic exercise alone 24. Aerobic training and combined
exercise training (aerobic/resistance) both lead to significantly increased mitochondrial
oxidative phosphorylation capacity (measured by high-resolution respirometry); however,
phosphorylation capacity, mRNA levels of mitochondrial transcription factors and
mitochondrial proteins were elevated to a greater extent following combined exercise
training 24.
It has been reported that the integration of aerobic exercise may potentiate the
skeletal muscle hypertrophic response to resistance exercise through a net increase in
protein turnover

28

. A recent study compared the skeletal muscle adaptations following

combined (aerobic/resistance) versus resistance only exercise

27

. Subjects were asked to

perform both cycling and maximal knee extensions exercising with one leg while
performing only maximal knee extensions with the other leg 27. In the leg that performed
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both exercises, vascular endothelial growth factor (VEGF), cAMP-response elementbinding protein (CREB) and mechanistic target of rapamycin (mTOR) were activated,
while these factors were unchanged in the leg that completed resistance only exercise

27

.

These genes are involved in myofibre growth and oxidative capacity, and their activation
following combined exercise suggests this approach may elicit a greater adaptation than
one exercise modality in isolation. Lastly, improvements in muscle oxidative capacity
associated with combined exercise may be due to the progressive nature of resistance-type
exercise. This is particularly relevant to the current data set as running intensity in the DAE
and DARE groups was not increased over the 12 weeks of training. Resistance training
resulted in a progressive increase in carrying capacity over the course of the training
program, indicative of improved muscular strength (see Table 3.1).
In the CD group, the increased intensity of ORO staining is coupled to increased
CD36 protein content and reduced CS activity. CD36 is a membrane protein involved in
long-chain fatty acid transport into skeletal muscle, and is associated with negative effects
on insulin responsiveness 37. The increased CD36 content in the CD group may account
for increased skeletal muscle lipid uptake. Circulating fatty acids (as well as triglycerides
and cholesterol) did not differ between groups, suggesting that increased lipid accumulation
was due to increased fatty acid uptake (via increased CD36) by skeletal muscle rather than
increased over supply of circulating free fatty acids from adipose stores. While it is not
clear as to the mechanisms leading to increased CD36 expression in T1D rats, the
membrane transporter protein has been shown to be upregulated following hyperglycemia
38

. To this point, it is interesting that DAE and DARE groups demonstrated a reduced

expression of CD36 despite being maintained at similar resting blood glucose levels (9-
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15mM). We have previously shown that at this intensity of aerobic exercise utilized in the
DAE and DARE groups, a significant and consistent drop in blood glucose is evident during
and following exercise 39. It is plausible that the acute reductions in blood glucose resulting
from each bout of aerobic exercise may have mitigated the increased expression of CD36
that was evident in the CD animals 40.
Contrary to our original hypothesis, we observed increased lipid staining in the
DARE group in comparison to DAE. It is important to note that ORO staining identifies
neutral lipid stores which would include both DAG and triacylglycerol (TAG) molecules.
While both the CD and DARE group demonstrate increased lipid staining, the composition
of neutral lipid stores in skeletal muscle may differ between these two groups. For instance,
the greater neutral lipid stores in DARE animals may be comprised of energy rich TAG
molecules rather than the insulin desensitizing DAG molecules

41

. TAGs do not exert

negative effects on the insulin signal, while saturated DAGs (i.e., di-C18:0) are tied to
insulin resistance as are membrane species of DAG

42

. Indeed, previous work from our

laboratory has shown that sedentary T1D (CD) animals demonstrate significant elevations
in skeletal muscle DAG content that are coupled to reductions in insulin sensitivity
measures 7. These observations in DARE animals are likely to be symbolize the reported
“athlete’s paradox” evident in highly trained individuals 43. Indeed, results from HOMAIR in the present study indicate the DARE group maintains insulin sensitivity compared to
the CD group, despite both showing similar intensities of skeletal muscle lipid staining.
While we attempted to quantify the phosphorylation status of IRS-1 on ser1101 to examine
the potential mechanism by which DAG may impede insulin signalling in CD animals, we
were unable to see discernible differences IRS-1 phosphorylation between CD and DARE
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animals. The lack of significant differences may be due to tissue status, as animals were
sacrificed three days post-exercise and were not fasted. It may also be that the skeletal
muscle lipid accumulation we observed here does not consist of saturated DAG species, as
saturated fatty acid incorporation into DAG is associated with insulin resistance in skeletal
muscle cells 7,42,44.
Lipin-1 is a phosphatidate phosphatase that regulates the balance between
phosphatidate and DAG in de novo synthesis of DAG and TAG from glyceraldehyde 3phosphate (G3P) 45. It is also a transcriptional coactivator of fatty acid oxidation genes and
has been linked to greater insulin sensitivity improvements 45. Lipin-1 mRNA increases in
skeletal muscle following exercise in rats

46

.

In the present study, DARE animals

demonstrate an exercise training-induced increase in Lipin-1 protein, without an increase
in CD36 protein. This uncoupling of Lipin-1 and CD36 may be indicative of greater de
novo DAG and TAG synthesis, which in turn, is associated with greater oxidative capacity
47

. In the DAE group, Lipin-1 protein content was not increased. It has been shown that

exercise-mediated increases in skeletal muscle Lipin-1 mRNA are regulated by
catecholamine-induced activation of the AMPK-β2-adrenergic receptor pathway

46

.

Resistance exercise is well documented to elicit a greater catecholamine response to
exercise than aerobic type exercise in patients with T1D 48. Further, it has been shown that
both aerobic and resistance training activate mTOR, with more robust effects observed
following resistance training 49. mTOR and its regulatory protein complex mTORC1 has
been shown to promote Lipin-1 translocation into the nucleus, where it regulates genes for
fatty acid oxidation

50

. Therefore, it is plausible that alterations in catecholamine levels
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and mTORC1 in the DARE group drives Lipin-1 expression and translocation may promote
a greater capacity for fatty acid storage and oxidation 27.
Combined exercise training results in greater oxidative capacity in skeletal muscle
of T1D rats. The integration of aerobic and resistance exercise may exert a synergistic
effect, producing greater adaptations than aerobic training alone. While combined exercise
training led to an increase in skeletal muscle lipid storage, this response is believed to be
characteristic of the “athlete paradox” whereby changes in lipid oxidation capacity lead to
greater lipid storage. Elevated levels of lipid storage mediator Lipin-1 and improvements
in insulin sensitivity that accompanied enhanced citrate synthase activity would support
this training specific adaptation. Given that combined resistance and aerobic exercise is a
useful strategy to reduce the risk of post-exercise hypoglycemia among T1D patients, the
integration of resistance and aerobic exercise may result in a safer exercise program while
potentiating metabolic adaptations to exercise in skeletal muscle to a greater extent than
aerobic training alone.
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CHAPTER 4
4

The Influence of Combined Aerobic and Resistance
Exercise Training versus Standard Intensive Insulin
Therapy on Insulin Resistance Development in a
Rodent
Model
of
Type
1
Diabetes
»

4.1 Introduction
Insulin resistance is characterized by an insufficient biological response to
circulating insulin and is critical in the pathogenesis of Type 2 Diabetes (T2D). More
recently, insulin resistance has been shown to occur in the presence of Type 1 Diabetes
(T1D), referred to as “double diabetes” 1. Individuals with both T1D and insulin resistance
are at a significantly higher risk of cardiovascular complications, as insulin resistance
contributes to the development of atherosclerosis via hyperglycemia, hyperinsulinemia,
and dyslipidemia 1,2.
The pathogenesis of insulin resistance in T1D is not fully understood. Several lines
of evidence would suggest that hyperglycemia or glucotoxicity is the primary driving force
underlying the development of insulin resistance. Hyperglycemia results in increased
hexosamine pathway activity, and activates stress-regulated pathways and the formation of
advanced glycation end products (AGEs) 3. On the contrary, others have demonstrated that
hyperglycemia is not the sole aspect of metabolic dysfunction contributing to insulin
resistance in T1D. Increased accumulation of intramyocellular lipid content leading to the
increased production of harmful lipid metabolites is believed to be a major contributor to
the pathogenesis of insulin resistance

4,5

. Termed glucolipotoxicity, it is likely that these

mechanisms are interrelated, as excess glucose can promote the accumulation of malonylCoA and diacylglycerol (DAG) in tissues including skeletal muscle 3.
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Regular exercise is a valuable tool for the maintenance of insulin sensitivity and
cardiovascular and metabolic health.

We have shown previously that regular aerobic

exercise restores insulin sensitivity in our rodent model of T1D, improves bone health,
neurovascular and endothelial function, and contributes to protection from ischemiareperfusion injury 6–9. However, the primary limitation to participation in regular exercise
among individuals with T1D is fear of hypoglycemia 10. Strategies to avoid post-exercise
hypoglycemia include reduction of insulin dose, ingestion of carbohydrates and brief, high
intensity efforts such as sprints at the initiation of an exercise bout

10,11

. The necessity of

carbohydrate ingestion has led many to question the benefit of exercise for patients with
T1D, as overcompensation with carbohydrate can compromise glycemic control

12

.

However, we have observed previously combined exercise in T1D rats with moderate
hyperglycemia (blood glucose 9-15 mM) produced significant improvements to oxidative
capacity, beyond that of aerobic exercise alone (Chapter 3). Further, combined (aerobic
and resistance) exercise training was associated with greater Lipin-1 protein content,
indicative of enhanced capacity to channel substrate toward neutral lipid storage (Chapter
3). Others have reported improved glycemic control, insulin sensitivity and body
composition among individuals with obesity and T2D following combined exercise 13–15.
Despite the known benefits of exercise, findings from large Diabetes Trials (such
as the DCCT (Diabetes Control and Complications Trial)) are the basis for recommending
intensive insulin therapy for the management of T1D. Findings from the DCCT include a
42% decrease in the risk of cardiovascular disease development in the intensively treated
group.

16,17

.

In further support for the prescription of intensive insulin therapy, a

retrospective analysis of the DCCT has revealed exercise does not improve microvascular
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outcomes in T1D

18

.

However, more recent analyses of DCCT results has revealed

methodological considerations and potential side effects associated with intensive insulin
therapy. Based on stringent exclusion criteria, patients were otherwise healthy and not
considered representative of the population of T1D patients

19

. Further, 33% of intensively

treated patients developed obesity compared to only 19.1% of conventionally treated
patients, and intensively treated patients gained nearly twice as much weight as
conventionally treated patients across all quartiles 20. This weight gain was accompanied
by increased blood pressure, triglycerides, total cholesterol and reduced high density
lipoprotein (HDL) cholesterol despite stable glycemic control in the intensively treated
group 20. It also has been suggested that insulin resistance serves as a better predictor for
coronary risk than HbA1C 19. Intensive treatment is problematic as it is associated with a
significantly increased risk of hypoglycemia, therefore limiting exercise participation

21

.

However, less stringent blood glucose control and combined exercise training is associated
with reduced post-exercise hypoglycemia risk, and induces significant metabolic
adaptations in skeletal muscle (Chapter 3).
We have shown previously combined exercise training induces similar, and
potentially even greater benefits to skeletal muscle lipid metabolism and insulin resistance
measures compared to aerobic exercise training alone. Given that combined training is
associated with reduced risk of post-exercise hypoglycemia, it may be considered a safer
modality for patients with T1D.

Despite this, intensive insulin therapy is currently

recommended to T1D patients. Therefore, the purpose of this study was to compare the
effects of intensive insulin therapy versus combined (aerobic + resistance) exercise on
insulin resistance and the distribution of lipid content (diacylglycerol vs. triacylglycerol) in
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skeletal muscle in our rodent model of T1D. We hypothesized that combined exercise
would be associated with enhanced insulin sensitivity in comparison to intensive insulin
therapy alone. Differences in insulin responsiveness would be consistent with the changes
in the type of fat storage whereby skeletal muscle of intensive insulin therapy would
demonstrate increased harmful DAG accumulation and combined exercise would favour
the accumulation of neutral, energy rich TAG.

4.2 Methods
Ethics Approval and Animals. Eight-week-old male Sprague-Dawley rats (Charles
River Laboratories) were used in this study. Animals were housed two per cage at constant
temperature and humidity, with a 12-h dark/light cycle, with access to water and standard
chow ad libitum. The experimental protocol followed the Principles of Laboratory Animal
Care (US NH publication No. 83-85, revised 1985). Ethics approval was obtained through
the University of Western Ontario Research Ethics Board, in accordance with Canadian
Council on Animal Care guidelines.
Experimental Groups. Animals were randomly divided into sedentary control (C,
n=20), sedentary control diabetic (CD, n=20), sedentary intensive insulin-treated diabetic
(DIT, n=20), and diabetic combined aerobic and resistance exercise (DARE, n=16). In each
of these groups animals were further divided into two subgroups The first subgroup
(n=8/group) of animals underwent the hyperinsulinemic-euglycemic clamp experiment
three days following their last bout of exercise (Experimental week #15) and were
sacrificed immediately after the clamp procedure. The remaining animals in each subgroup
(C, n=12; CD, n=12; DIT, n=12; DARE, n=8) did not undergo a hyperinsulinemic-
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euglycemic clamp and were sacrificed three days following their last bout of exercise
(Experimental week #15) in order to assess baseline measures.
Diabetes Induction. Rats were housed for one week to familiarize with their
surroundings. After one week (Experimental week #1), T1D was induced with multiple
low-dose STZ injections (Experimental week #2).

For five consecutive days, STZ

(20mg/kg; Sigma Aldrich, Oakville, ON, Canada) was injected into the intraperitoneal
cavity 22. Insulin pellets (LinShin, Toronto, ON, Canada) were implanted following two
consecutive non-fasting blood glucose readings of ≥ 18.0 mmol/L). Blood glucose was
monitored throughout the duration of the study and insulin pellets/dosages were adjusted
accordingly. Blood glucose in the CD and DARE groups was maintained between 9-15
mmol/L to mimic poorly controlled T1D, while blood glucose in the DIT group was
maintained between 5-9 mmol/L, reflective of intensive insulin therapy.
Exercise Training.

Following diabetes induction, rats in the DARE group

underwent a familiarization protocol followed by 12 weeks of exercise training
(Experimental weeks #4-15). Familiarization was performed over five days, alternating
between one day of aerobic exercise (treadmill running) and one day of resistance exercise
(weighted ladder climbing).

Treadmill familiarization consisted of progressively

increasing running up to 27 m/min on a six percent grade daily for five days. Small blasts
of compressed air were used to encourage rats should they cease running and break a
photoelectric beam at the rear of the treadmill. Rats were also familiarized to resistance
training, and performed 10 vertical ladder climbs per day with weights attached to the base
of the tail, corresponding to 5%, 15%, 20%, and 35% of body mass. Following the
familiarization week (Experimental week #3), training consisted of alternating days of one
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hour treadmill running at 27 m/min on a six percent grade, and climbing sessions consisting
of climbing with 50%, 75%, 90% and 100% of maximum lifting capacity. Maximum lifting
capacity was re-tested every fourth day of resistance training using the sequential addition
of 30 grams of weight until exhaustion.
Hyperinsulinemic-Euglycemic Clamp. Three days after the completion of the final
exercise bout (Experimental week #15), the first set of animals underwent a
hyperinsulinemic-euglycemic clamp to assess insulin resistance. Animals were overnight
fasted for twelve hours and anaesthetized using isoflurane and an intraperitoneal injection
of urethane (25 mg/kg)/α -chloralose (4 mg/kg) 23,24. Rats were removed from isoflurane
and the anesthetic injection maintained anaesthesia. A catheter was surgically inserted into
the right jugular vein for insulin (Novolin ge Toronto, Novo Nordisk, ON, Canada) and
glucose infusion. A second catheter was surgically inserted into the right carotid artery for
arterial blood glucose sampling. Insulin was infused at 10 mU/kg/min; 0.4 µ IU/mL, and
glucose was infused at 20 mg/kg/min (0.2 g/mL). Arterial blood glucose was sampled
every 5 minutes until 20 minutes and every 10 minutes thereafter. Glucose infusion rate
(GIR) was adjusted to maintain blood glucose at the “clamped” value of 4-6 mmol/L.
Blood glucose values and GIR was recorded for 90 minutes and reported for the final 20
minutes of the clamp .
Tissue Collection. The first set of animals was sacrificed upon completion of the
hyperinsulinemic-euglycemic clamp, which occurred three days after the last bout of
exercise (Experimental week #15). The second set of animals did not undergo the clamp
procedure and were sacrificed three days following the last bout of exercise (Experimental
week #15). Animals were sacrificed via gas anaesthesia followed by exsanguination and
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cardiac excision. Soleus muscles were removed and immediately flash frozen in liquid
nitrogen and stored at -80°C for later analysis.
Thin Layer Chromatography. Lipid was extracted from 200-300 mg of minced
soleus muscle. Tissue was submerged in chloroform: methanol (2:1, v:v) and placed in the
dark for one hour. The extract was poured over Whatman filter paper into a glass test tube.
The extraction vessel was rinsed and vortexed with 1 mL chloroform:methanol solution,
filtered, and added to the original extract. Samples were dried under air stream in a 3040°C water bath. The extract was weighed and diluted in chloroform:methanol (2:1). Lipid
extracts, diacylglycerol (1-Palmitoyl-3-Oleoyl-sn-Glycerol) and triolein (Avanti Polar
Lipids Inc. Alabama USA) were spotted on glass plates with a silica gel matrix (Analtech
TLC uniplates, Sigma Aldrich, Canada). Plates were immersed in a few centimeters of
mobile phase consisting of toluene:methanol (7:3, v:v). Samples and standards were
visualized using Iodine ACS Reagent (Sigma Aldrich, Canada) in a glass chamber and
images were obtained with a flatbed scanner for analysis using ImageJ.
Data Analysis and Statistics. Animal mass, blood glucose, food intake, and glucose
infusion rate during hyperinsulinemic-euglycemic clamp were assessed via one-way
ANOVA with Tukey’s post hoc test. Diacyglycerol and Triacylglycerol content was
assessed via two-way ANOVA with Tukey’s post hoc test. Statistical analyses were
performed with SigmaPlot, graphs were generated using GraphPad Prism.
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4.3 Results
Animal Characteristics and Food Intake. All diabetic rats (CD, DIT, DARE)
weighed significantly less than non-diabetic control animals (p<0.05) (Fig.4.1). Intensively
insulin treated animals (DIT) weighed significantly more than DARE animals (p<0.05)
(Fig.4.1). Blood glucose in all diabetic groups (CD, DIT, DARE) was significantly higher
than C (p<0.05) (Fig.4.2.). DIT blood glucose was significantly lower than CD and DARE
(p<0.05) (Fig.4.2.). The number of pellets implanted for blood glucose management
throughout the course of the study was significantly higher in the DIT group compared to
CD and DARE (p<0.05) (Table 4.1). Further, food intake was assessed at week 3 of
training (Experimental week #6) in the hyperinsulinemic-euglycemic clamp subgroup, and
was significantly higher in CD compared to C (p<0.05) (Table 4.1).
Insulin Resistance Measures.

Glucose infusion rate (GIR) during the

hyperinsulinemic-euglycemic clamp was significantly lower in CD compared to C, DIT
and DARE (p<0.05), indicative of insulin resistance. GIR in the DARE group was
significantly higher than in C, CD and DIT, indicative of enhanced insulin sensitivity
among the exercise trained animals (p<0.05). (Fig.4.3).
Soleus Muscle Lipid Content. Soleus Diacylglycerol content was significantly
increased in DIT following hyperinsulinemic-euglycemic clamp (p<0.05) (Fig.4.4.A). The
increase in DAG content in the CD group approached significance (p=0.09) (Fig.4.4.A).
Triacylglycerol content was significantly increased in CD and DARE following
hyperinsulinemic-euglycemic clamp (p<0.05) (Fig.4.4.B).
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*
#

Figure. 4.1. Animal mass (g) for the duration of the study. (*) C rats weighed significantly
more than CD, DIT and DARE rats (p<0.05). (#) DARE rats weighed significantly less
than DIT rats (p<0.05).
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#

*

Figure. 4.2. Weekly blood glucose (mmol/L) for the duration of the study. (*) C blood
glucose was significantly lower than CD, DIT and DARE (p<0.05). (#) DIT blood glucose
was significantly lower than CD and DARE (p<0.05).
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Table 4.1. Food intake and number of insulin pellets. (°) Food intake in the
hyperinsulinemic-euglycemic clamp subgroup was significantly higher in CD compared to
C (p<0.05). (*) Total number of pellets implanted over the duration of the study was
significantly greater in DIT compared to CD and DARE (p<0.05).
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#

*

Figure. 4.3. Hyperinsulinemic-Euglycemic Clamp for assessment of insulin resistance.
Groups were compared during the final 20 minutes of the clamp when animals were at or
near steady-state GIR. (*)GIR in CD was significantly lower than in C, DIT and DARE
(p<0.05). (#) GIR in DARE was significantly higher than in C, CD and DIT (p<0.05).
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*

∆

Figure. 4.4. Soleus lipid content. A. Diacylglcyerol (DAG) Content. (*) There was a
significant increase in DAG in DIT following hyperinsulinemic-euglycemic clamp
(p<0.05). B. Triacylglycerol (TAG) Content. There was a significant increase in TAG in
CD (#) and DARE (∆) following hyperinsulinemic-euglycemic clamp (p<0.05).
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4.4 Discussion
The purpose of this study was to compare the effects of combined exercise training
versus standard intensive insulin therapy on skeletal muscle lipid content and insulin
resistance development in a rodent model of T1D. Consistent with our hypothesis, we
observed enhanced insulin sensitivity following combined exercise training compared to
intensive insulin therapy.

Further, we observed increased skeletal muscle DAG

accumulation in intensive insulin therapy-treated animals following a hyperinsulinemic
clamp, which did not reach signficance in the combined exercise trained group (with
conventional insulin therapy). Combined exercise training appeared to favour significant
increases in the energy–rich TAG accumulation following the hyperinsulinemic clamp.
Analysis of two subgroups (hyperinsulinemic-euglycemic clamp animals and unclamped
animals) provided insight into the effects of acute glucose and insulin stimulation on
skeletal muscle lipid content. Excess glucose uptake into skeletal muscle may drive
malonyl-CoA formation, resulting in inhibition of CPT-1 and increasing the pool of fatty
acyl-CoA and DAG 25.
The gold standard for assessing insulin resistance development in humans is the
hyperinsulinemic-euglycemic clamp 26. Here, we report a significant reduction in glucose
infusion rate in the CD group compared to C and DIT. This would support previous work
demonstrating the negative impact of hyperglycemia on insulin sensitivity 3,27. It has been
reported that the onset of T1D is associated with skeletal muscle DAG accumulation
resulting from increased adipose tissue lipolysis, and an increase in PKCθ activity, which
directly interferes with the insulin signalling pathway 28. Several lines of evidence have
shown that impaired insulin signalling is further potentiated as T1D progresses, leading to

108
decreases in mitochondrial oxidative capacity and impaired lipid oxidation 29. Indeed, our
laboratory has reported a reduction in citrate synthase activity and increased DAG in
skeletal muscle of conventionally treated T1D rodents (Chapter 2,3).
Although hyperglycemia and/or glucotoxicity may in part drive the development of
insulin resistance 3, findings from the present study reveal that hyperglycemia itself may
not be the primary cause of insulin resistance. Rather, insulin resistance may develop from
an interaction between hyperglycemia and abnormal lipid accumulation in skeletal muscle
referred to as glucolipotoxicity. Hyperglycemia contributes to insulin resistance via
increased hexosamine pathway activity, producing UDP-N-acetylgalactosamine (UDPGalNAc) which O-GlNAcylates IRS-1 and GLUT-4

3,30

. An important finding of the

current study is that the DARE group exhibited a significant enhancement of insulin
sensitivity, despite the maintenance of blood glucose between 9-15 mmol/L in both the
DARE and the CD groups. We have previously shown increased DAG as well as insulindesensitizing lipid metabolites in a conventionally treated group that were ameliorated with
aerobic training 6. These findings support the concept of glucolipotoxicity, whereby
hyperglycemia drives the accumulation of diacylglycerol, which directly inhibits PKCθ to
impair insulin signalling 3.
In the DIT group, intensive insulin therapy was used to maintain blood glucose
between 5-9 mmol/L for the duration of the study, and reduced the severity of insulin
resistance in this group compared to the conventionally treated animals. However, insulin
sensitivity in the DARE group was significantly higher than the DIT group, suggesting that
reducing hyperglycemia alone is not sufficient to enhance insulin sensitivity.

This

phenomenon has also been observed in a clinical setting 31. A three-stage hyperinsulinemic-
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euglycemic clamp performed on T1D patients revealed significant whole-body insulin
resistance compared to non-diabetic subjects

31

. Among the T1D patients, HbA1c was

7.7%, indicative of good glycemic control. Three days prior to the clamp procedure,
patients wore a continuous glucose monitoring device, and glucose was normalized with
variable insulin infusion overnight. Whole-body insulin resistance was therefore not
entirely attributable to hyperglycemia, and these findings suggest other factors may
contribute to insulin resistance among individuals with T1D.
Combined exercise resulted in significantly enhanced insulin sensitivity compared
to C, CD and DIT. This was accompanied by increased skeletal muscle TAG content
following the hyperinsulinemic-euglycemic clamp. We have previously shown aerobic
exercise training effectively restores insulin sensitivity in T1D rodents, however, these
findings are the first from our lab to show enhanced insulin sensitivity with combined
exercise training 6. It is possible that an increase in neutral lipid stores (TAG) is coupled
to increased oxidative capacity (as we have previously shown (Chapter 3)) effectively
reducing the accumulation of harmful lipid intermediates such as DAG despite a lack of
stringent blood glucose control with exogenous insulin.
Increased soleus TAG in the DARE group is likely mediated by increased
diacylglycerol acyltransferase 1 (DGAT1), which aids in channeling fatty acid substrate
into TAG, reducing DAG and ceramide accumulation

32

. Transgenic overexpression of

DGAT1 in type 1 muscle fibres protects mice from high fat diet induced insulin resistance
32,33

. This exercise-mediated shift in fatty acid channeling may result in a metabolic state

similar to the “athlete’s paradox”, in which skeletal muscle maintains insulin sensitivity
despite increased TAG content

32,33

.

Maintenance of insulin sensitivity in these
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circumstances is likely the result of reduced lipid (DAG)-induced activation of PKC
isoforms and JNK, as fatty acids are directed toward TAG as opposed to DAG 33.
Interestingly, TAG was also increased in skeletal muscle of the CD group, despite
a significant reduction in insulin sensitivity.

Hyperglycemia and exogenous insulin

administration may account for some of this accumulation, as they have an additive effect
on DGAT1 activity 34. Further, insufficient oxidative capacity may contribute to elevated
TAG content in CD animals. Our previous findings align with others who have shown T1D
is associated with reduced oxidative capacity, potentially mediated by lipid peroxidation,
and inhibition of mitochondrial biogenesis with insulin treatment (Chapter 3)

29

. Taken

together, increased TAG in the CD group suggests lipid accumulation is pathological in
nature in sedentary T1D, stemming from reduced oxidative capacity, and is associated with
insulin resistance. Conversely, increased TAG in the DARE group is an adaptation to
exercise, accompanied with increased oxidative capacity and is not associated with
impaired insulin signalling.
Soleus muscle DAG content was significantly increased in the DIT animals
following the hyperinsulinemic clamp. Insulin has been shown to increase DAG via de
novo phosphatidic acid synthesis

35

. Insulin stimulates increased activity of glycerol-3-

phosphate acyltransferase, resulting in phosphatidic acid synthesis and conversion into
DAG 35. The use of insulin pellets to maintain stringent blood glucose control may account
for this finding in the DIT group. Interestingly, Lipin-1 protein converts phosphatidic acid
into DAG, and we have previously observed increased Lipin-1 protein content in skeletal
muscle of conventionally treated TID rodents (Chapter 3). The CD group in the present
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study did not demonstrate a significant increase in DAG following the clamp, however the
differences approached statistical significance (p=0.09) perhaps indicative of a trend.
It is important to note that the DAG-PKC interaction differs according to the DAG
species involved, as saturated DAG are associated with insulin resistance and unsaturated
DAG are not

36

. DAG containing C16:0, C18:0, C18:1, C18:2 and C20:4 have a strong

association with PKCθ activation among obese and T2D patients 4. The subcellular
location of DAG may also contribute to its involvement in insulin signalling, as well as the
training status of individuals tested, as insulin signalling is preserved in endurance athletes
37

. Further work should investigate whether DAG composition (ie. saturation) differs

between sedentary and exercise trained T1D rats and its relationship to insulin sensitivity.
Combined aerobic and resistance exercise is effective for enhancing insulin
sensitivity in a rodent model of T1D, even in the context of moderate hyperglycemia.
Intensive insulin therapy was sufficient to attenuate the drastic decline in insulin sensitivity
observed with conventional insulin therapy. Altered insulin sensitivity was observed in
parallel with changes in skeletal muscle lipid content, further supporting the role of
lipotoxicity in the development of insulin resistance.
In conclusion, combined exercise training and maintenance of moderate glycemic
control is significantly more effective for the enhancement of insulin sensitivity compared
to intensive insulin therapy. These findings indicate exercise-induced alterations in skeletal
muscle lipid metabolism, including enhanced oxidative capacity (Chapter 3) and greater
sequestration of fatty acids as neutral TAG stores underlie these effects.
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CHAPTER 5
5

«General Discussion»

5.1 Summary
The principal objective of this dissertation was to better understand the relationship
between skeletal muscle lipid metabolism and insulin resistance in a rodent model of T1D.
The second objective was to examine the effect of both exercise modality and insulin
therapy to enhance muscle lipid metabolism and whole body insulin sensitivity. In the
context of T2D and metabolic syndrome, insulin resistance manifests due to increased
skeletal muscle lipid metabolites which directly interact with the insulin signalling cascade
1

. The rise of insulin resistance among individuals with T1D is associated with an increased

risk of cardiovascular complications, and emerging evidence suggests a potential role for
skeletal muscle lipids in the pathogenesis of insulin resistance in this population 2. Trials
such as the Diabetes Control and Complications Trial (DCCT) have led to the promotion
of intensive insulin therapy and stringent glycemic control as the optimal management
strategy for T1D. However, evidence suggests that hyperglycemia itself is not the primary
factor contributing to insulin resistance, and that disturbances in lipid metabolism may also
be an important factor

3–5

. It is well documented that engaging in regular exercise

significantly improves skeletal muscle lipid accumulation and insulin sensitivity among
T2D and metabolic syndrome populations, and is recommended for patients with T1D to
mitigate the development of several diabetic-related complications 6,7.
The main findings of this thesis were as follows; (1) sedentary, moderately
hyperglycemic T1D rats develop insulin resistance and have increased skeletal muscle lipid
metabolites, which is ameliorated with aerobic exercise training (Chapter 2), (2) sedentary
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T1D rats have reduced skeletal muscle oxidative capacity coupled to increased fatty acid
transport capacity. While aerobic exercise alone restores oxidative capacity, combined
exercise training (resistance and aerobic) leads to greater improvements, and is coupled to
a greater capacity to sequester lipid within skeletal muscle (Chapter 3), and (3) combined
exercise training in the context of moderate hyperglycemia significantly enhances insulin
sensitivity, oxidative capacity and neutral lipid storage in T1D rats. While intensive insulin
therapy is sufficient to prevent the dramatic decline in insulin sensitivity observed in
sedentary T1D rodents, combined exercise training induces significantly greater
improvements to insulin sensitivity in T1D rats (Chapter 3,4).
To fulfil the objectives of this dissertation, it was necessary to determine whether
insulin resistance and exercise training were associated with alterations in skeletal muscle
lipid metabolites in our model of T1D. We employed an aerobic exercise training protocol
as this modality is associated with a variety of metabolic and cardiovascular improvements
in our model of T1D

8–11

. In skeletal muscle of obese and T2D individuals, increased

skeletal muscle triglyceride is linked to insulin resistance 12. Evidence suggests this is also
a characteristic of T1D, as intramyocellular lipid content is associated with insulin
resistance in patients with T1D

13

. Further, STZ-induced diabetic rats have increased

neutral lipid staining and fatty acid transporter (FAT/CD36) protein content

14

. These

metabolic alterations have been proposed to stem from hormonal changes coupled to
hyperglycemia, and also include reduced oxidative enzyme capacity

15

. Consistent with

these findings, metabolomic analysis of the red portion of the gastrocnemius muscle
revealed several lipid metabolites differentiated muscle of sedentary, insulin resistant T1D
rats from nondiabetic rats and aerobically trained rats (Chapter 2). Muscle from sedentary,
insulin resistant rodents was unique from that of nondiabetic and exercise trained T1D
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animals as it was characterized by octadecenoic acid, linoleic acid, arachidonic acid,
docosahexaenoic acid and palmitic acid. These fatty acids have been linked to insulin
resistance through the formation of inflammatory cytokines, direct interaction with proteins
in the insulin signalling cascade and reduction of GLUT4 expression in vitro 16–18. Further,
diacylglycerol, a lipid species well-known to contribute to insulin resistance due to its
interaction with PKCθ, was significantly increased in muscle of sedentary T1D rats 19,20.
Interestingly, while aerobic exercise was sufficient to restore insulin sensitivity in
T1D rodents, it was not sufficient to enhance insulin sensitivity beyond that of a sedentary
nondiabetic animal. Previous observations from our laboratory show aerobic exercise
significantly enhances insulin sensitivity in nondiabetic animals, however we did not
observe the same robust effect in T1D rodents

21

. In patients with T1D, metabolomics

analysis indicates altered muscle metabolism following exercise in comparison to nondiabetic individuals, evidenced by attenuated Krebs cycle intermediates in circulation postexercise 22. These findings, coupled to our observations following metabolomic analysis
of skeletal muscle, suggests altered muscle metabolism in our rat model of T1D, which
may necessitate a unique or increased stimulus to elicit similar adaptations to exercise.
Hypoglycemia is a major barrier to engaging in regular exercise among patients
with T1D

23

. Aerobic exercise, despite eliciting several metabolic and cardiovascular

adaptations and improving overall health and well-being, is associated with substantial,
acute, blood glucose reductions 24. Resistance training is emerging as an exercise modality
associated with a reduced risk of hypoglycemia and as a strategy to prevent aerobicexercise-induced hypoglycemia 25. Among trained T1D patients, blood glucose during and
after resistance exercise is more stable, compared to aerobic exercise

26

.

Further,

performing a bout of resistance exercise prior to aerobic exercise is effective in reducing
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the severity of post-exercise hypoglycemia among T1D patients

27

. It is believed that the

increase in epinephrine and norepinephrine may account for the blood glucose stabilizing
effects of this exercise modality 25. We have previously shown increased GLUT4 protein
in the white portion of the gastrocnemius following resistance training, as well as an
improvement in insulin sensitivity 8.

There is also increasing evidence to suggest that

combined exercise training, consisting of aerobic and resistance modalities produces
greater fitness adaptations than each modality in isolation 28. Aerobic exercise performed
prior to resistance exercise has also been show to significantly enhance the muscle
transcriptome associated with resistance exercise, and is effective in reducing HbA1c and
cholesterol in patients with T2D 6,29. Accordingly, the second objective of this thesis was
to establish the efficacy of combined exercise training for improving skeletal muscle lipid
metabolism and oxidative capacity in our model of T1D. We began by quantifying citrate
synthase enzyme activity as a marker of oxidative capacity (Chapter 3). Consistent with
the literature, we observed a significant reduction in citrate synthase enzyme activity in
sedentary T1D animals

15

. This was also coupled to an increased fatty acid transporter

protein content, suggesting an increase in fatty acid entry into the muscle without an
accompanying increase in oxidative capacity.

Aerobic exercise effectively restored

oxidative capacity in T1D animals, however, combined exercise exerted a significant
increase in oxidative capacity. Combined exercise was also associated with increased
protein content of Lipin-1, an essential enzyme to allow the esterification and storage of
free fatty acids. Taken together, we proposed that combined exercise elicits significant
improvements to skeletal muscle lipid oxidation and storage. Given the role of insulin
resistance in the development of cardiovascular disease, it was of importance to ensure that
the improvements in insulin sensitivity we observed with aerobic exercise (Chapter 2) were
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not lost when combined with resistance exercise. Therefore, Chapter 4 examined the
effects of combined exercise on insulin sensitivity in T1D rats.
Stemming from the findings of the DCCT, the current recommended insulin
treatment regime for T1D patients is intensive insulin therapy with the target of maintaining
normal HbA1c (approximately 6.5%) through multiple daily insulin injections or an insulin
pump device

30

. Intensive insulin therapy is still considered the most highly effective

treatment strategy for patients with T1D, as a 42% reduction in the risk of cardiovascular
disease development has been reported in these patients

3,31

. However, recent follow up

studies of DCCT participants have revealed a significantly higher rate of obesity in the
intensively insulin treated patients, as well as an increased levels of circulating lipids 32.
Some also suggest the exclusion criteria in this cohort study was problematic, excluding
T1D patients with a history of cardiovascular disease, hypertension, dyslipidemia, and
neuropathy requiring treatment

30

. This resulted in the inclusion of an otherwise healthy

population of T1D patients, not considered representative of the average population with
T1D 4. It also remains unclear as to whether intensive insulin therapy is associated with
increased insulin resistance, although emerging findings indicate an association between
intensive insulin therapy and the development of obesity, metabolic syndrome and insulin
resistance

3,32

.

Insulin resistance is a critical component in the pathogenesis of

cardiovascular disease, and is often improved with exercise training

33–35

. However,

intensive insulin therapy is the current recommended therapy in the management of T1D,
and participation in exercise training, especially aerobic exercise, is problematic for this
population 23.
The third objective of this thesis was to compare the effects of intensive insulin
therapy versus combined exercise training on insulin sensitivity and lipid metabolism
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(Chapter 4). We also sought to examine whether the composition of skeletal muscle lipids
(diacylglycerol and triacylglycerol) differed between these treatment strategies (exercise
vs. intensive insulin therapy). What may be the most critical finding from this experiment
is that the pathophysiology of insulin resistance is not in accordance with the “glucose
hypothesis”, whereby hyperglycemia is the causative factor underlying the onset of
complications in T1D 30. Consistent with previous reports21, glucose infusion rate (GIR)
during the hyperinsulinemic-euglycemic clamp was significantly decreased in sedentary
conventionally treated T1D rats (CD), the moderately hyperglycemic group with glucose
maintained between 9-15 mM for the duration of the study. GIR in the intensively treated
T1D group (DIT), with glucose maintained between 5-9 mM for the duration of the study,
was restored to that of nondiabetic control animals. These findings demonstrate that in the
sedentary state hyperglycemia drives insulin resistance, supporting the importance that
stringent blood glucose control through exogenous insulin administration is efficacious in
the preservation of insulin sensitivity. However, the combined exercise treated (DARE
group) was maintained in the same glycemic range as the CD group for the duration of the
study, with glucose between 9-15 mM, and GIR was substantially increased compared to
all other groups. Therefore, despite moderate hyperglycemia, combined exercise elicited a
significant improvement in insulin sensitivity, implicating factors other than hyperglycemia
in the pathogenesis of insulin resistance. Glucolipotoxicity occurs when hyperglycemia
drives lipid storage and the production of insulin-desensitizing lipid metabolites 36. In the
DARE group, increased oxidative capacity and lipin-1 protein content (Chapter 3) may, at
least in part, be a potential mechanism by which exercise-trained animals drive high
circulating blood glucose toward oxidation or storage as neutral TAG stores, which are also
increased in this group (Chapter 4). By channeling substrate toward oxidation or storage
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as neutral TAG, combined exercise training may induce favourable adaptations in skeletal
muscle and protect against the glucolipotoxic effects of hyperglycemia on insulin
signalling.
5.2 Conclusion
Upon completion of this dissertation, there are two significant findings that
contribute to our understanding of insulin resistance in T1D. 1) The pathogenesis of insulin
resistance is attributable to abnormal skeletal muscle lipid accumulation and potential
inability to effectively metabolically channel excess substrate. This may be amplified by
hyperglycemia, manifesting as glucolipotoxicity, and 2) Combined exercise training is a
more effective treatment strategy than intensive insulin therapy for the enhancement of
insulin sensitivity in T1D.
We consistently observed that sedentary lifestyle in T1D was associated with
skeletal muscle lipid accumulation and insulin resistance. However, the increase in insulindesensitizing lipid metabolites in skeletal muscle with both moderate hyperglycemia and
intensive insulin treatment suggests that hyperglycemia alone does not account for insulin
resistance, and that glucolipotoxicity is a significant driver of insulin resistance. While
insulin sensitivity is restored with stringent glucose lowering, combined exercise training
significantly enhances insulin sensitivity. In addition to enhanced insulin sensitivity,
combined exercise training significantly increases oxidative capacity and neutral
triglyceride content. These findings are perhaps best described as “running water carries
no poison” 37, whereby the proper oxidation, storage and channeling of lipids in the skeletal
muscle cell (as an adaptation to combined exercise training) prevents the accumulation of
insulin-desensitizing metabolites. This can be achieved through the implementation of
combined exercise training while maintaining moderate hyperglycemia as opposed to strict
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glycemic control with intensive insulin therapy alone. Further, exercising while in a
moderately hyperglycemic state substantially reduces the risk of hypoglycemia. Initiating
exercise at an elevated blood glucose concentration can help ensure that post-exercise
concentrations would not fall into a hypoglycemic range. Collectively, this work suggests
that combined exercise training may be a superior exercise modality for patients with T1D,
as it induces significant adaptations in skeletal muscle. Most notably, combined exercise
training may reduce the risk of cardiovascular complications in T1D by enhancing insulin
sensitivity and preventing the onset of “Double Diabetes”.
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Appendices
Appendix A. Multiple Low-dose Streptozotocin Protocol (rat)
PURPOSE:

Diabetes induction in rats.
PROCEDURE:

Preparing 5X Citric Acid/Citrate Buffer
1.   For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate
ii. 23.8g Sodium Citrate Dihydrate (Sigma)
Mix into iii. 175mL of MilliQ water
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH)
2.   Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml mark (pH
will move slightly). If satisfied with the pH, adjust volume in a 250 ml graduated cylinder
and filter in a 0.2µm filter.
3.   Store at room temperature. This is your 5X stock solution.
Making up Streptozotocin (STZ) for Injection
1.   Place 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of distilled water filtered
through a 0.2µm syringe filter. Check the pH. This gives you a working concentration of
153 mM
2.   The desired pH is between 4.5-4.7. Under the fume hood, add 1 drop at a time of
concentrated HCl to the buffer, checking pH in between until desired pH is reached.
3.   Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe filter
as before). Check pH again.
4.   STZ must be injected within 15 minutes of preparation. Weigh STZ based on calculations
below:
Inject 20mg/kg of STZ per animal. If the average weight of 10 animals is 200g, then
20mg/kg X 0.2kg = 4 mg/animal. To account for solution lost in filtering, weigh extra. Ie.
(4mg (per animal) X 12 rats = 48 mg total (0.048 g).
5.   Dissolve the STZ into buffer by vortexing then sterile filter using a 0.2µm syringe filter.
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution
4mg ÷ 16mg/mL solution = 0.25mL
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Injecting and Follow-Up of the Animals
1.   Inject each rat intraperitoneally with a dose of 20mg/mL within 15 minutes of solution
preparation.
2.   Dispose containers in a biohazardous waste receptacle and needles in a sharps container.
3.   Record the date of STZ injection and add a biohazard label to the cage (leave biohazard label
on cage for at least 3 days following the last injection).
4.   Repeat this procedure the following day.
5.   Check blood glucose daily. Diabetes is achieved with two non-fasting blood glucose
readings of >18 mmol, which is usually achieved after 5-8 injections (i.p. 20mg/kg).
REFERENCES:

Low dose STZ induction protocol. Animal Models of Diabetic Complications Consortium
AMDCC Protocols. 2003
O’Brien BA, Harmon B V, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for the
development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178: 176–181,
1996.
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model of
poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise training.
Diabetes Metab 39: 226–235, 2013.
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Appendix B. Insulin Pellet Implantation (rat)
PURPOSE:

Exogenous insulin administration in diabetic rats.
PROCEDURE:

1.  

Anesthetize the animal with isoflurane machine set to 4-5% with an O2 rate of 1
L/min. Once animal is unconscious, remove it from the chamber and place in the
nose cone. Reduce isoflurane to 3% to maintain the plane of anesthesia.

2.  

Shave a small area on the abdomen where the pellet will be implanted.

3.  

Apply 10% providone-iodine solution to the skin, followed by 70% ethanol, to
disinfect the site of insertion.

4.  

Make a small subcutaneous incision.

5.  

Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse
with saline and insert into subcutaneous region.

6.  

Use 1 pellet for the first 350g of body weight.

7.  

Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providoneiodine solution over the opening.

8.  

Close the incision by suturing.

9.  

Place the animal under a heat lamp and monitor until it recovers from anesthesia.

10.  

Record on the cage card that insulin pellets have been implanted.

REFERENCES:

Wang, Paul Y. "Sustained-Release Implants for Insulin Delivery", in Biotechnology of Insulin
Therapy, Pickup, John C., ed., Chapter 3, pp 42-74, Blackwell Scientific, London UK (1991).
http://www.linshincanada.com
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Appendix C. Hyperinsulinemic-Euglycemic Clamp (rat)
PURPOSE:

To assess insulin sensitivity in an anesthetized animal.
CATHETERIZATION PROCEDURE:

1.  

Turn on heating pad, prepare anesthetic in a clean beaker on a heated stir platform:
Urethane 1.0g/10 ml ddH2O
α-Chlorolose 160mg/10 ml ddH2O
Let the solution cool before preparing syringes for injection.

2.  

Prepare glucose and insulin:
2.0g dextrose/4 ml saline (500 mg/ml solution)
50 µl of 100 U/ml Toronto insulin in 12.5 ml saline + 1% bovine serum albumin (0.4
U/ml or 400 mU/ml solution)

3.  

Prepare saline with heparin:
Combine heparin (Sigma Aldrich, Canada, 210-6) with saline for a final
concentration of (27 U/ml). (This should work out to approximately 6 vials of heparin
per bag of saline but be sure to check the heparin concentration and adjust
accordingly).

4.  

Prepare two PE50 or PE90 tubing catheters as follows:

5.  

Prepare surgical field with neck support, hooks, suture silk, tape and anesthetic
syringe. For intraperitoneal injection of anesthetic: (mass (g) / 4) / 100 = ml for
injection
ie. for a 300g rat injection volume = (300/4) /100 = 0.75 ml anesthetic

6.  

Anesthetize the animal with isoflurane machine set to 4-5% with an O2 rate of 1
L/min. Once animal is unconscious, remove it from the chamber and place in the
nose cone. Reduce isoflurane to 3% to maintain the plane of anesthesia. Inject
approximately ½ the anesthetic dose, and allow animal to stabilize for 10-20 min.
Gradually wean the animal off isoflurane and maintain anesthesia with the
urethane/α-chlorolose injection.
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7.  

Make a central incision with scissors from along the esophagus and blunt dissect to
the right of the esophagus.

8.  

Expose and clean the jugular vein:
- using #7 tweezers, slip a piece of suture silk under the vein and tie the cranial
portion of the vein.
- using #7 tweezers, slip a piece of suture silk under the vein and throw a knot at the
cardiac portion of the vein but do not cinch down the suture.
- make a small incision in the vein, insert and advance the venous catheter toward the
cardiac suture. Cinch down the cardiac suture over the catheter and pull back on the
syringe to ensure blood flow. Tie the catheter to the cranial suture to ensure it is
secure in the vein.

9.  

Expose and clean the carotid artery:
- blunt dissect between the trachea and jugular vein.
- expose and clean the carotid artery.
- set three sutures: one on the cranial portion of the artery (cinch), one at the cardiac
portion of the artery (cinch) and throw one suture between the cranial and cardiac
portions but do not cinch this down.
- make a small incision in the artery, insert and advance the arterial catheter toward
the cardiac suture.
- tie down the middle suture around the catheter in the artery.
- loosen the cardiac suture, advance the catheter and cinch down the cardiac suture
over the artery and catheter.
- Tie the catheter to the cranial suture to ensure it is secure within the artery.
- open the stopcock and check for blood flow in the catheter. Immediately flush the
line with heparinized saline to prevent clotting.

10.  

Inject the remaining ½ dose of anesthetic intraperitoneally and allow the animal to
stabilize for approximately 20 minutes.

HYPERINSULINEMIC-EUGLYCEMIC CLAMP PROCEDURE:

1.  

Connect syringes to infusion pumps.

2.  

Begin glucose and insulin infusion. Start glucose infusion at 20 µl/min and adjust
accordingly based on blood glucose values. Insulin infusion remains constant at 10
µl/min/

3.  

Measure blood glucose every 5 minutes until 20 minutes and every 10 minutes
thereafter from the arterial line using a Freestyle Lite blood glucose monitor. Record
blood glucose values and adjust and record the glucose infusion rate.

4.  

Continue the clamp for 90 minutes, “clamping” the animal’s blood glucose between
4-7 mmol/L.

5.  

Record the total volume of insulin and glucose infused during the clamp.
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Appendix D. Metabolomics: High Performance Liquid Chromatography coupled
to Quadrupole Time-of-Flight Mass Spectrometry (HPLC-QTOF-MS)
PURPOSE:

To identify metabolites in rat skeletal muscle samples.
SAMPLE PREPARATION:

1.  

Weigh and cut 100 ± 3mg of tissue.

2.  

Homogenize tissue in 250 µl ice cold HPLC grade acetonitrile containing isatin (5
µg/ml) and flurazepam (25 ng/ml) as internal standards for 2 minutes on an ice bath.

3.  

Vortex samples, centrifuge at 14 000 rpm at 4°C for 5 minutes.

4.  

Remove 120 µl of supernatant and dilute with 30 µl ultrapure water. The final
sample should contain 80% acetonitrile.

5.  

Generate a control injection consisting of a pooled sample of an equal volume of all
injected samples.

6.  

Transfer samples to vials and inject 1 µl in triplicate from each vial.

CHROMATOGRAPHIC SEPARATION:

1.  

Separate using a Waters Acquity Ultra Performance Liquid Chromatography system,
with an Acquity UPLC HSS T3 column (1.8 µm particle size, 100 mm x 2.1 mm).

2.  

Set column temperature to 45°C in Waters ACQUITY UPLC I-Class System
(Waters, Milford, MA).

3.  

Set the mobile flow: 0.45 ml/min, consisting of water (A) and acetonitrile (B) each
with 0.1% formic acid. Set the following UPLC conditions:
0-2 min: 1-60% B
2-6 min: 60-85% B
6-8 min: 85-99% B
8-10 min: 99-1% B

4.  

For mass spectrometry, use a Waters XevoTM G2S-QTofMS, and measure
metabolites in positive and negative electrospray ionization mode.
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5.  

Set capillary voltage to 2 kV and cone voltage to 40 V, set the source temparture to
150°C.

6.  

Set desolvation gas flow to 1200 L/h at 600°C and cone gas flow to 50 L/h.

7.  

Set the lockmass at 500 ng/ml leucine-enkephalin at a flow rate of 10 µl/min,
measuring every 10 seconds and averaged over 3 scans.

8.  

Data acquisition: centroid mode using MSE method with m/z range of 50-1200.
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Appendix E. Homogenizing Protocol
PURPOSE:
To prepare skeletal muscle samples for Western Blotting.
PROCEDURE:
1.   Prepare homogenizing buffer:
100 mmol/L NaCl
50 mmol/L Tris base
0.1 mmol/L EDTA (ethylenediaminetetraacetic acid)
0.1 mmol/L EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid  
1% Tritonx100
pH 7.5
2.   Cut and weigh 0.1 g of muscle sample.
3.   Place in Eppendorf tube or glass test tube.
4.   Add homogenizing buffer for a 1:10 ratio. Ie. 0.0957 g tissue to 957 µl homogenizing
buffer.
5.   Repeat for each sample.
6.   Homogenize sample and centrifuge homogenates.
7.   Pipette homogenate into Eppendorf tube and freeze at -70°C.
8.   Determine protein content of sample using Bradford Protein Assay (See Appendix F)
prior to use.
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Appendix F. Bradford Protein Assay
PURPOSE:
To determine protein content of sample homogenate.
PROCEDURE:
	
  

1.   Dilute 1 part dye (Bio-Rad 500-0006) with 4 parts ddH2O.
2.   Filter the solution with Whatman 1 filter paper
3.   Label a microplate template sheet with sample ID and standard.
4.   Label a second set of Eppendorf tubes with each sample ID and standard.
5.   In the second set of tubes, add 5 µl of sample and 95 µl of ddH2O.
6.   Pipette standards and samples into microplate as follows:

0
1
2
3
4
5

BSA : Water
+
200µl reagent
1
2
3
0 + 10
1+9
2+8
3+7
4+6
5+5

Add 10µl of mixed sample + 200µl reagent
(everything done in 3’s)

4

5

6

7

8

9

10

11

12

7.   Shake microplate and Incubate at room temperature 5 to 60 minutes. Read at 595 nm.
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Appendix G. Western Blotting Protocol
SAMPLE PREPARATION:
1.   Thaw homogenized samples on ice.
2.   Assess the amount of protein to be loaded in each well. Running a loading curve may be
necessary to visualize the ideal amount for a given protein of interest.
3.   Label a new set of Eppendorf tubes with sample IDs and dilute the sample (determined
from the Bradford Assay) in sample buffer (see Western Blotting solutions #4) in a 1:1
ratio and vortex thoroughly.
4.   Boil the samples for up to 5 minutes (depending on protein of interest).
5.   Bring samples back to room temperature before loading in gel.
POLYACRYLAMIDE GEL PREPARATION:
1.   Clean mini glass plates with 70% ethanol and assemble gel cassette.
2.   Prepare separating gel according to chart below:
(% of acrylamide in the gel depends on the size of the protein of interest, example below
is for a 10% gel).
1 Gel
4 ml
3.33 ml

ddH2O
30% Acrylamide
(in fridge)
Separating Buffer 2.5 ml
10% SDS
100 µl
10% APS
62.5 µl
(in fridge: 0.1g in
1ml DDH2O)
TEMED
(in fumehood)

6.25 µl

10% Separating Gel
2 Gel
4 Gel
8 ml
16 ml
6.67 ml 13.3 ml

6 Gel
24 ml
20 ml

8 Gels
32 ml
26.7 ml

5 ml
200 µl
125 µl

10 ml
400 µl
250 µl

15 ml
600 µl
375 µl

20 ml
800 µl
500 µl

12.5 µl

25 µl

37.5 µl

50 µl

3.   Pour separating gel using pipette and be careful to avoid bubbles. Overlay the gel with
water saturated isobutanol. This will prevent bubbles from forming and will ensure a
continuous charge from separating to stacking gel.
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4.   Wait 30-60 minutes for the gel to polymerize and rinse the overlay solution with ddH2O
and dry with filter paper.
5.   Prepare stacking gel according to chart below and pour over separating gel:
ddH20
30% Acrylamide
(in fridge)
Stacking Buffer
10% SDS
10% APS
(in fridge)
TEMED
(in fumehood)

1 Gel
3.05 ml
0.65 ml

2 Gel
6.1 ml
1.3 ml

4 Gel
12.2 ml
2.6 ml

6 Gel
18.3 ml
3.9 ml

8 Gels
24.4 ml
5.2 ml

1.25 ml
50 µl
31.3 µl

2.5 ml
100 µl
62.6 µl

5 ml
200 µl
125 µl

7.5 ml
300 µl
188 µl

10 ml
400 µl
250 µl

6.25 µl

12.5 µl

25 µl

37.5 µl

50 µl

6.   Place the lane comb in the stacking gel between the two glass plates. Allow to
polymerize for 30-60 minutes.
7.   Prepare 1L of 1x running buffer (see Western Blotting Solutions #6) for every 2 gels and
keep in refrigerator.
8.   Gently remove lane comb from stacking gel and fill wells with 1x running buffer.
GEL ELECTROPHORESIS:
9.   Load the sample and ladder into the wells using a micropipette with a loading tip.
10.  Once loaded, place gels in running unit, fill with cold 1x running buffer, and be sure to
fill the space between the gels as well.
11.  Runn gels between 50-70 V until the samples have moved through the stacking gel
(approximately 30 minutes) and then 120 V until samples travel completely through the
gel.
12.  While the gels are running, prepare the transfer buffer (see Western Blot Solutions #7)
and store in refrigerator.
TRANSFER TO NITROCELLULOSE MEMBRANE:
13.  Cut filter paper and nitrocellulose membranes to the same size as the gel. Soak with
Brillo pads in cold transfer buffer.
14.  Gently separate gel from the glass pate and place in transfer buffer. Assemble the
transfer apparatus “sandwich” as shown below:
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15.  Place “sandwich” in the transfer tank, add ice packs and fill with cold transfer buffer.
16.  Run the transfer at 70 V for 90 minutes and keep cold on ice. Note, the transfer voltage
and time may differ depending on the size of the protein of interest.

(-‐ve)	
  -‐	
  BLACK	
  
Brillo	
  Pad	
  
Filter	
  Paper	
  
Gel	
  
Nitrocellulose	
  
Filter	
  Paper	
  
Brillo	
  Pad	
  
(+ve)	
  -‐	
  RED	
  

BLOCK AND INCUBATE MEMBRANES:
17.  Prepare 1L of 1x TBS (see Western Blot Solutions #7 “10X TBS”) for every 2
membranes.
18.  When the transfer is complete, remove the membrane from the “sandwich” and place in a
container with 5% blocking solution (see Western Blot Solutions #9). Incubate for 1
hour on shaker at room temperature.
19.  Prepare primary antibody.
20.  Incubate membranes in primary antibody solution overnight at 4°C (incubation time may
vary depending on antibody manufacturer instructions).
21.  Wash the membranes 3 times in TTBS (see Western Blot Solutions #8) on a shaker for 510 minutes.
22.  Prepare secondary antibody (HRP conjugated) solution.
23.  Incubates membranes for 1 hour on shaker at room temperature.
24.  Wash the membranes 3 times in TTBS (see Western Blot Solutions #8) on a shaker for 510 minutes.
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CHEMILUMINESCENT IMAGING:
25.  Prepare the substrate (BioRad ImmunStar Western C chemiluminescence kit (#1705070))
by combining 500 µl of the Luminol/enhancer solution and 500 µl of the peroxide
solution into a 1.5 ml Eppendorf tube.
26.  Place the membrane on a transparency and pipette 1 ml of the mixed solution over the
blot.
27.  Close the chemidoc door and proceed to image the membrane.
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WESTERN BLOTTING SOLUTIONS:
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SEPARATING GEL:
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STACKING GEL:
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Appendix H: Thin Layer Chromatography
PROCEDURE: All sample preparation and chromatography must be done in a fume hood.
1.   Weigh and cut 200-300 mg of muscle. Mince well using a blade and place in a 14 ml
falcon tube.
2.   Add 8 ml of chloroform:methanol (2:1, v:v). Cap and keep dark in fume hood for 1 hour.
3.   Weigh a set of glass test tubes and record the weight for each tube.
4.   Pour the extract from the falcon tube over Whatman 2 filter paper into the glass test tube.
Add 3 ml of chloroform:methanol (2:1) to the falcon tube, vortex, and pour into the test
tube.
5.   Repeat for all samples.
6.   Dry the sample in the glass tube under a steady air stream in a 30-40°C water bath for
approximately 1 hour or until all the chloroform:methanol has evaporated.
7.   Obtain the weight of the sample by weighing the tube and subtracting the weight of the
empty tube previously recorded.
8.   Reconstitute the sample to 0.5 ml/g-1 wet weight.
9.   Line a glass dish with filter paper, and pour in approximately 1 inch of toluene:methanol
(7:3, v:v).
10.  Spot 5 µl of sample along a line approximately 1-1.5 inches from the bottom of the plate.
Spot standards on the left and right of the plate.
11.  Cover the plate in the toluene dish with a lid or wrap with foil to minimize evaporation.
12.  Let sit in the fume hood and run the solution to the top of the plate.
13.  In a separate dish, add a few grams (5-10) of Iodine ACS reagent. Cover the dish to keep
the vapors from evaporating.
14.  Remove the plate from the toluene:methanol container and let dry briefly.
15.  Place the plate in the chamber with the Iodine ACS reagent but do not place the plate
directly on the crystals.
16.  Cover the dish and let it sit for 1-2 hours until desired intensity of spots is reached.
17.  To quantify the plate, place it in a clear plastic sleeve and scan on a flatbed scanner. The
sample spots may be quantified with ImageJ.

146	
  
	
  

Appendix I: Citrate Synthase Enzyme Activity Assay
SAMPLE PREPARATION:
1.   Prepare homogenizing buffer:
3.404 g KH2PO4 (monobasic)
4.355 g K2HPO4 (dibasic)
0.9510 g EDTA
0.9510 g EGTA
add to 400 ml ddH2O
pH to 7.4 and top up to 500 ml with ddH2O
2.   Weigh and cut 0.1 g of skeletal muscle and add to sample buffer (1:20) in a glass test
tube.
3.   Homogenize.
4.   Re-dilute homogenate: 50 µl homogenate + 950 µl buffer.
5.   Freeze-fracture samples: freeze in -70°C freezer, remove, let thaw completely, and freeze
again. Repeat this process three times.
6.   Prepare Tris buffer:
100mM Tris, pH 8.3
CITRATE SYNTHASE ASSAY:
7.   Turn on the plate reader, choose a kinetic protocol and set it to read for 2 minutes (6
readings, 20 seconds apart at 405 nm)
8.   Prepare Oxaloacetate (OAA) (5mM):
1.321 mg dissolved in 1 ml Tris buffer
Prepare Acetyl CoA (aCoA) (3mM):
3.1 mg dissolved in 1 ml ddH2O
Prepare 5,5’-Dithiobis (2-nitrobenzoic acid) (DTNB) (5mM):
3.96 mg dissolved in 10 ml Tris buffer
9.   Label a 96-well plate with sample IDs (only run a few samples at a time, as the reaction
starts immediately).
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10.  Pipette samples in triplicate as follows:
2 µl sample + 184 µl Tris buffer + 2 µl DTNB
11.  Immediately before reading, add 2 µl CoA and 10 µl OAA
12.   Record the mOD/min value (be sure the reaction is linear and reaches a plateau. Activity

can be calculated with the following equation:
Where A405/min is the rate, V(ml) is the total volume of the well, DF is the dilution factor,
εmM is the DTNB extinction coefficient, L(cm) is the microplate path length, and Venz(ml)
is the sample volume.
	
  
∆𝐴)*+ / min×𝑉	
   𝑚𝑙 ×𝐷𝐹
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = ∆𝐴)*+ / min
𝜀 89	
   ×𝐿	
   𝑐𝑚 ×𝑉;<= (𝑚𝑙)
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Appendix J: Histochemistry: Oil Red O Stain for Neutral Lipids
PROCEDURE A:
1.   Obtain frozen skeletal muscle sections 10-12 µm in thickness.
2.   Prepare ORO stock solution:
2.5 g Oil Red O (Sigma Aldrich, Canada)
400 ml isopropyl alcohol (99%)
stir for 2 hours
3.   Prepare ORO working solution:
Mix 1.5 parts stock solution to 1 part ddH2O
Cool in fridge
Filter through Whatman filter paper
4.   Remove slides from freezer and allow to thaw to room temperature.
5.   Place slides in coplin jar with workings solution for 10 min to 1 hour.
6.   Rinse with ddH2O for 2-5 min.
7.   Mount slides with aqueous mounting media (10% phosphate buffered saline and 90%
glycerol). Aqueous mounting media is essential, using another mount may result in stain
being extracted from the lipid in the sample.
PROCEDURE B:
1.   Obtain frozen skeletal muscle sections 10-12 µm in thickness.
2.   Circle sections with liquid blocking pen and pipette 500 µl (or enough to cover without
evaporating) 0.5% ORO in propylene glycol (Sigma Aldrich, Canada).
3.   Leave slides in fume hood for approximately 12 hours.
4.   Rinse with ddH2O for 2-5 min.
5.   Mount slides with aqueous mounting media (10% phosphate buffered saline and 90%
glycerol). Aqueous mounting media is essential, using another mount may result in stain
being extracted from the lipid in the sample.
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